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ABSTRACT 
The administrated dose of a drug is adjusted to give a therapeutic effect in patients 
without causing side-effects or toxicity. Cytochrome P450 (P450) and UDP-
glucuronosyltransferase (UGT) enzymes, uptake and efflux transporters and nuclear 
receptors regulating these enzymes, expressed in the liver and in other tissues, are all 
important players in drug metabolism, disposition and elimination. Many drugs are 
substrates and/or inhibitors of the same enzymes and may cause drug-drug interactions 
(DDIs) in a patient that takes several drugs at the same time, which can result in loss of 
therapeutic effect, side-effects or toxicity. The detection of major metabolites, reactive 
metabolites, metabolizing enzymes and transporter proteins for all new drug candidates 
is of high importance during preclinical evaluations. Reliable in vitro test systems of 
the human liver are essential for a complete and accurate preclinical evaluation of a 
new drug candidate. Primary human hepatocytes lose their hepatic functions within a 
few hours or days when maintained in suspension or cultured in two-dimensions (2D).  
 
In this work, important hepatic functions were investigated in the human hepatoma cell 
line, HepaRG, and fresh human hepatocytes in suspension and in a dynamic three-
dimensional (3D) bioreactor system. Fresh human hepatocytes cultured in 3D retained 
P450, UGT and OATP1B1 uptake activities for at least one week. Further, all major in 
vivo metabolites of AZD6610 and diclofenac were detected in “fresh” human 
hepatocytes after 6 days culture in 3D. Three P450 enzymes, CYP2J2, CYP4A11 and 
CYP4F3B, which are normally not involved in the metabolism of drugs, were 
identified to take part in the hydroxylation of AZD6610. Furthermore, the UGT activity 
was higher and the P450 and OATP1B1 activities were lower in HepaRG cells 
compared to primary human hepatocytes, for the model substrates evaluated in this 
study. The HepaRG cells maintained P450 activities for several weeks and UGT 
activities for at least one week in the bioreactor culture. Moreover, effects of rifampicin 
and ketoconazole on P450 activities in HepaRG cells cultured in the bioreactor 
predicted well the effects observed in vivo. The primary human hepatocytes and 
HepaRG cells were polarized in the bioreactor and formed tissue-like structures, which 
resembled the human liver tissue. In addition, the detection of glucuronides in the 
bioreactor medium indicated an active efflux of conjugated metabolites from 7 days old 
primary human hepatocytes cultured in the bioreactor back to the circulating medium. 
Knockdown of drug transporters in Caco-2 cells using short hairpin RNA (shRNA) was 
shown to be a valuable tool to understand potential sites of transporter-mediated 
pharmacokinetic interactions and the involvement of hepatic transporters in drug 
disposition. This model clearly showed the involvement of P-gp but not of MRP2 in the 
efflux of ximelagatran, hydroxy-melagatran and melagatran. The liver bioreactor using 
either fresh human hepatocytes or HepaRG cells retained biotransformation and 
transporter capacities for at least one week. This is a compelling feature of the 3D 
model, which open up for long-term cultures required for detection of metabolites from 
slowly metabolized drugs as well as induction, DDI and toxicity investigations. 
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1 INTRODUCTION 
 
 
1.1 GENERAL INTRODUCTION 
Drugs available on the market aim to improve health and survival of patients 
worldwide. However, changed efficacy, toxicity and side-effects may occur due to 
polymorphic enzymes or in patients using several drugs at the same time. 
 
Most drugs are taken orally and undergo first pass metabolism in the intestine and liver 
before entering the systemic blood circulation. The metabolizing enzymes, uptake and 
efflux transporters expressed in the tissues together with the physical chemical 
properties of the drugs determine the pharmacokinetics of the drug including 
absorption, distribution, metabolism and excretion (Curatolo, 1998). Knowledge and 
identification of processes and certain enzymes involved in the pharmacokinetics of 
new drug candidates, revealed during drug development, will increase the success rate 
of drugs reaching the market and facilitate the design of relevant drug-drug interaction 
(DDI) clinical studies, that are needed to appropriately label a drug for safe and 
effective use (Giacomini et al., 2010).  
 
The liver is a critical organ for the bioavailability and metabolism of drugs. Freshly 
isolated human hepatocytes represent a good model of the liver since they are able to 
perform the full range of in vivo drug biotransformation pathways and retain many of 
the uptake and efflux functions of liver cells (De Bartolo et al., 2006). However, the use 
of fresh human hepatocytes has several drawbacks such as scarce and unpredictable 
availability, inter-donor variability and significant variation in cell functions, especially 
cytochrome P450 (P450) activities (Luo et al., 2002; Ohtsuki et al., 2012; Rogue et al., 
2012; Schaefer et al., 2012). The loss of liver specific functions in freshly isolated cells 
may partly be explained by the rupture of the three-dimensional (3D) structure of the 
tissue. In contrast, hepatoma cell lines can be cultured under longer periods of time and 
are often used for detection of acute toxicity, whereas functions important for 
investigation of in vivo relevant metabolites and chronic toxicities are absent. 
 
Thus, preclinical drug metabolism, pharmacokinetic and safety research are lacking 
reliable in vitro tools to predict the metabolic fate, DDIs and toxicity of drugs in the 
liver. The limitation of the in vitro system described above is a major problem for the 
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pharmaceutical industry and can results in delayed deliveries and even withdrawal of 
drugs from the market.  
 
Three-dimensional cultures of human hepatocytes may help to establish an improved in 
vitro tool for drug discovery and development. It has been shown that well-perfused 
liver cells cultured in a 3D bioreactor retain in vivo like properties and form tissue like 
structures, enabling liver specific functionality to be extended over at least two weeks 
(Zeilinger et al., 2004; Schmelzer et al., 2009). Further, the human hepatoma cell line, 
HepaRG, exhibits promising features expressing important functions for drug 
disposition such as P450 enzymes, UDP-glucuronosyltransferase (UGT) enzymes, 
nuclear receptors and transporter proteins that resemble those found in primary human 
hepatocytes (Aninat et al., 2006; Le Vee et al., 2006; Kanebratt and Andersson, 
2008b). Recently, HepaRG cells were evaluated as a valuable in vitro model for 
prediction of P450 induction by drugs in vivo in human (Kanebratt and Andersson, 
2008a).  
   3 
1.2 LIVER STRUCTURE AND FUNCTION 
 
The liver plays a central role in several essential processes in the body, including the 
metabolism of cholesterol, carbohydrates, fatty acids and amino acids. The organ is 
also of great importance in the protection against and detoxification of endogenous and 
foreign substances (xenobiotics).  
 
 
1.2.1 Cell types 
 
The organ is composed of many different cell types, which are divided into 
parenchymal cells (hepatocytes) and non-parenchymal cells. 80% of the liver tissue 
volume consists of hepatocytes responsible for the uptake, metabolism and storage of a 
great variety of substances, including drugs. The non-parencymal cells include 
endothelial cells, hepatic stellate cells (fat-storing cells), biliary epithelial cells and 
immune cells such as Kupffer cells (Figure 1) (Gumucio et al., 1996).  
 
 
 
 
Figure 1. Overview of the liver structure: Hepatocytes and sinusoidal capillaries between the portal triad 
(bile duct, portal vein and hepatic artery) and central vein in the hepatic lobule are shown in A. Further, 
the bile canaliculi formed between the hepatocytes, the sinusoid between the hepatocyte cords as well as 
endothelial cells, stellate cells and kupffer cells are present in B. 
Figure 1A is adapted from Cunningham and Van Horn (2003) with permission from the publisher. 
 
 
1.2.2 Structure 
 
The hepatic lobule is the structural and functional unit of the liver (Rappaport et al., 
1954). The hepatocytes in the lob are arranged in radial cords from the peripheral part 
to the centre and each hepatocyte is exposed to a mixture of venous blood (from portal 
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(branch)
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vein) and arterial blood (from hepatic artery) to provide sufficient oxygen and enabling 
good transport of metabolites (Figure 1). The mixed blood flow from the vein and 
artery to the central vein in the vascular channels, the sinusoids, formed in the space 
between the hepatocyte cords. The endothelial cells form the walls of the hepatic 
sinusoids and Kupffer cells are located in the sinusoids (Figure 1) (Rappaport et al., 
1954; Angelin et al., 1988; Ishibashi et al., 2009). This structure is important in 
directing the excretion of the products of biotransformation out of the hepatocytes into 
the bile and/or the blood. The hepatocytes secrete bile into the bile canaliculi formed 
between the hepatocytes, which eventually ends up in bile ducts (Figure 1B). 
Hepatocytes facing the blood side are located at different positions between the portal 
vein/hepatic arteries and the central vein and are exposed to different concentrations of 
oxygen and nutrients, which results in different gene expressions and distinct functional 
capabilities (Rappaport et al., 1954; Allen et al., 2005).  
 
 
 
 
Figure 2. Overview of the processing of xenobiotics in the hepatocyte: P450s and other hepatic enzymes 
such as conjugating enzymes, UGT and sulphotransferase (SULT) are important in the metabolism of 
xenobiotics. The endoplasmic reticulum, where the enzymes are located, is shown in dark blue. Further, 
the cellular membrane has many transporters, OATPs, OCTs and ABC transporters, which are important 
for the transmembrane flux of many xenobiotics including the products of the conjugating enzymes 
(Sevior et al., 2012). The figure is from Sevior et al., 2012, with permission from the publisher. 
 
 
   5 
1.2.3 General functions 
 
One of the most important functions of the liver is the transformation of carbohydrates 
from the diet and the storage of it as glycogen, which can be converted to glucose via 
glycogenolysis when needed, thus regulating the level of glucose in the blood. New 
glucose is also produced by converting glucose precursors such as lactate and glycerol 
to glucose (gluconeogenesis). The glucose homeostasis is mainly regulated by insulin 
and glucagon. Insulin increases the uptake of glucose to the liver and inhibits the 
glycogenolysis and increase the synthesis of glycogen, whereas glucagon increases the 
production of glucose in the liver (Angelin et al., 1988). The liver also take up and 
metabolize amino acids, which are used for biosynthesis of protein (e.g. clotting 
factors, lipoprotein and albumin), with rest products such as glucose and urea. The 
proteins are synthesized by ribosomes in the rough endoplasmic reticulum. The rough 
and smooth endoplasmic reticulum constitute an extensive mesh in the cell where the 
latter (Figure 2), incorporates many of the biotransformation enzymes, while others are 
found in the cytosol (Sevior et al., 2012). 
 
The biotransformation enzymes P450s and UGTs and the membrane bound transporters  
such as organic anion-transporting polypeptides (OATPs) in the hepatocytes, play an 
important role in the first pass metabolism and bioavailability of drugs together with 
gut wall enzymes and bacterial enzymes (Kato, 2008; Wu et al., 2011). The first pass 
metabolism is a protective function of the body to prevent or reduce the entry of 
xenobiotics. The foreign substances can be transported back into the gut or 
biotransformed to more polar substances and excreted by transporters into bile or urine 
(Figure 3). Thus, drug metabolizing enzymes and drug transporters are co-operating to 
reduce the bioavailability and increase excretion of administrated drugs (Benet, 2009; 
Wu, 2012). It is essential to understand which particular enzymes that interferes with a 
certain drug to avoid DDIs, side-effects as well as complications with polymorphic 
enzymes (Ingelman-Sundberg et al., 2007; Close, 2012). The expression and function 
of drug transporters and metabolizing enzymes in animals used in preclinical 
development do not always reflect the expression and functions in human (Cao et al, 
2006;  Katoh et al., 2006; Li et al., 2009). Therefore, reliable human in vitro models are 
desired for evaluation of drug metabolism and disposition in vivo in human. 
 
 
1.3 DRUG METABOLISM 
 
Drug metabolism takes place in several organs and tissues. The most important organ is 
the liver followed by intestine (including intestinal microflora), kidney, lungs, brain, 
skin, placenta, plasma and many more. Drug metabolism reactions are normally 
classified as phase I and phase II reactions. Phase I reaction involves functionalization 
and phase II reaction results in conjugation, of the drug or metabolite. 
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1.3.1 Phase I metabolism  
 
The term functionalization implies the creation of a functional group or the 
modification of an existing one and it includes all important redox reactions and 
hydrolysis/hydrations. There are several oxidoreductases involved in xenobiotic 
metabolism and the P450s is the far most significant enzyme family estimated to 
metabolize approximately 70-90% of all drugs and drug candidates. Other important 
enzymes are flavin-containing monooxygenases (FMOs), known to catalyze some 
reactions in parallel with P450s, aldo-keto reductases, alcohol and aldehyde 
dehydrogenases as well as hydrolases.  
 
 
1.3.1.1 Cytochrome P450 (P450) 
 
The evolution of P450 enzymes involved in drug metabolism appears to have been 
driven by the need for versatile enzymes capable of coping with a variety of substrates. 
P450 families 1, 2 and 3 mainly metabolize xenobiotics, whereas P450 families 4-51 
are involved in essential physiological functions like oxidations of fatty acids, 
biosynthesis of biliary acid as well as biosynthesis and metabolism of cholesterol and 
steroid hormones (Testa and Krämer, 2008). 
 
In humans, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 
and CYP3A4 (Table 1) are of particular importance in the metabolism of drugs and a 
universal and univocal nomenclature system is used to describe the different isoforms 
and their evolutionary relationships. For example, the nomenclature of the CYP3A4 
gene is, CYP (root), 3 (family), A (sub-family) and 4 (individual gene) (Nelson et al., 
2004). 
 
Structurally, P450s are containing a rigid heme-binding core and a highly flexible distal 
side which is likely to be involved in substrate binding and product release, because the 
majority of the access/egress active site channels identified to date are located in this 
region. Experimental techniques and molecular dynamics simulations indicate that both 
CYP3A4 and its substrate binding active site exhibit a remarkably high degree of 
flexibility. In contrast, CYP1A2 and CYP2A6 are more rigid, while CYP2C9 and 
CYP2D6 exhibit intermediate flexibility. This suggests that there may be a relationship 
between active site flexibility and substrate promiscuity, because CYP3A4 is highly 
promiscuous, while CYP1A2 and CYP2A6 are more selective in binding their 
substrates (Otyepka et al., 2012). 
 
Further, P450s are mainly located in the endoplasmic reticulum (Figure 2) (Edwards et 
al., 1991)  together with NADPH-cytochrome P450 reductase, NADH-cytochrome b5 
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reductase and cytochrome b5, which are components of the electron-transfer systems 
(Masters and Marohnic, 2006). For many typical oxidative reactions, P450 enzymes 
utilize O2 and two electrons supplied by NADPH to catalyze the monooxygenation of 
numerous exogenous and endogenous substrates (Hrycay and Bandiera, 2012). 
 
Unexpected pharmacokinetic properties, efficacy and side-effects of drugs in patient 
are often related to polymorphic P450 enzymes or interactions with co-administrated 
drugs that are substrates, inducers or inhibitors of P450 enzyme(s) (Hisaka et al., 2010). 
Especially elderly patients, taking several drugs at the same time, may suffer a 
significant harm from DDIs and thus an increased risk for hospitalization (Hines and 
Murphy, 2011). For example, CYP3A4, CYP2D6, CYP2B6 and CYP2C9 are often 
recognized as potential sites of DDIs and the CYP3A4 inhibitor ketoconazole is known 
to increase the area under the plasma concentration versus time curve (AUC) in vivo for 
several CYP3A4 substrates (Hisaka et al., 2010). Further, the polymorphic nature of 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 can affect the 
therapy outcome and polymorphic P450 enzymes are estimated to influence 20–25% of 
all drug therapies (Table 1) (Ingelman-Sundberg, 2004; Johansson and Ingelman-
Sundberg, 2011).  
 
Table 1. In vivo P450 probe substrate, inhibitors, nuclear receptors, inducers and functional effects of 
P450 polymorphisms. 
 
(1) - (3) The information is a selection from tables present in the FDA Draft Guidance for Industry - Drug 
Interaction Studies: 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm 
(4) Functional effects of polymorphic P450 enzymes. From Johansson and Ingelman-Sundberg, 2011 
(Table 1). 
 
 
1.3.1.2 Dehydrogenases/reductases 
 
Alcohol dehydrogenases, aldehyde dehydrogenases, aldo-keto reductases, short-chain 
dehydrogenases/reductases and quinone reductases are all enzyme families of 
importance in drug metabolism (Oppermann and Maser, 2000), which are mainly found 
in the cytoplasm. The enzymes are expressed in several tissues including the liver, 
kidney and brain etc. (Penning et al., 2000; Belyaeva, 2003; Nishimura and Naito, 
2006; Marchitti et al., 2010).  
P450
In vivo  probe
substrate
(1)
In vivo 
inhibitor
(2)
Nuclear
receptor
In vivo
 inducer
(3) Functional effects
(4)
CYP1A2 Caffeine, theophylline Fluvoxamine AhR Tobacco smoke Rare
CYP2B6 Bupropion, efavirenz Clopidogrel CAR (PXR) Rifampicin Reduced drug metabolism
CYP2C8 Repaglinide, paclitaxel Gemfibrozil PXR (CAR) Rifampicin Reduced drug metabolism
CYP2C9 Celecoxib, warfarin Amidarone PXR (CAR) Rifampicin Very significant
CYP2C19 Omeprazole, S-mephenytoin Ticlopidine PXR (CAR) Rifampicin Very significant
CYP2D6 Dextromethorphan, pimozide Paroxetine None known Very significant
CYP3A4 Midazolam, quinidine Ketoconazole PXR (CAR) Rifampicin No or small
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Interestingly, a recently identified enzyme in the outer mitochondrial membrane, 
molybdenum cofactor sulfurase C-terminal containing 2 (MOSC2), has been recognize 
to be direct involved in the amidoxime reductase activity. Thereby playing an important 
role in the activation of prodrugs containing amidoximes, such as the direct thrombin 
inhibitor ximelagatran (studied in Paper I) and its follow-up compound AZD0837 
(Eriksson et al, 2003; Deinum et al, 2009), by reducing the prodrugs to the bioactive 
amidines (Neve et al., 2012). 
 
 
1.3.1.3 Hydrolases 
 
Hydrolases take part in non-redox reaction involving H2O as a reactant and are of major 
interest in the metabolism of drugs, prodrugs and other xenobiotics. The hydrolases 
with major significant in drug metabolism are carboxylesterases, cholinesterases, 
paraoxonase and epoxide hydrolases (Testa and Krämer, 2008). They are expressed in 
plasma, liver, brain, lung, small intestine etc. and located in the cytoplasm and 
endoplasmic reticulum (McCracker et al., 1993a; McCracker et al., 1993b).  
 
 
1.3.2 Phase II metabolism 
 
Conjugation requires a suitable functional group in the substrate, which will serve as 
the anchoring site for an endogenous molecule or moiety such as methyl, sulphate, 
glucuronic acid or glutathione. The endogenous conjugating moiety is usually carried 
by a cofactor and the reactions are in most cases catalysed by transferases bringing the 
substrate and cofactor close enough to allow the reaction to proceed. The anchoring site 
may already be present in the xenobiotics or created by the phase I reaction as 
described above. The conjugation of xenobiotics has a protective function as it often 
forms a less reactive product and enables excretion by increased hydrophilicity (Testa 
and Krämer, 2010). However, some conjugations may cause toxicity since the products 
are reactive or products are accumulated in the tissue as residues and reach toxic levels 
(McCarver and Hines, 2002). Interestingly, it is believed that a co-evolution of 
transferases and transporters have occurred, thus coupling the formation of polar 
conjugates and their active excretion by drug transporters (Jeong et al., 2005).  
  
The conjugation reactions can be divided into methylations, sulfonations, 
phosphorylations, glycosidations including glucuronidations, acetylations, formations 
of coenzyme A conjugates and glutathione conjugations. The glucuronidations and 
formation of glutathione conjugates are common reactions in xenobiotics metabolism 
(Testa and Krämer, 2010). There the glutathione and glutathione S-transfereases have 
evolved as a major chemical protection against reactive xenobiotics and reactive 
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compounds produced during metabolism of endogenous and exogenous compounds 
and play a critical role in cellular protection against oxidative stress and radiations 
(Mitchell et al., 1988; Okada et al., 2011; Raza, 2011). 
 
 
1.3.2.1 Glucuronidations 
 
UDP-glucuronosyltransferases (UGTs) are known to catalyze the highly diverse 
reactions of glucuronidation and facilitate the reaction by binding the substrate and 
cofactor uridine-5’-diphospho-α-D-glucuronic acid (UDPGA). The glucuronic acid is 
transferred from the cofactor to the substrate and attached to a nucleophile, forming O-, 
N-, S- or C-glucuronides (Dutton, 1980). The human UGTs are the products of four 
gene families, UGT1, UGT2, UGT3 and UGT8 (Mackenzie et al., 2005) and are 
located in the membrane of the smooth endoplasmic reticulum (Figure 2) (Meech and 
Mackenzie, 1998). The UGTs are detected in different tissues including the liver, 
kidney, gastrointestinal tract, reproductive organs and the skin (Peters and Janson, 
1988; Ohno and Nakaji, 2009).  The isoforms found in the liver are UGT1A1, 
UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A9, UGT2B4, UGT2B7, 
UGT2B10, UGT2B15 and UGT2B17 (Ohtsuki et al., 2012; Ohno and Nakaji, 2009; 
Court, 2010) and some of the substrates are alcohols, phenols, carboxylic acids, amines, 
amides, bile acids and bilirubin (Tephly et al., 1988). Similar to the CYP families, 
polymorphisms have been reported in the UGT 1 and 2 families (Court, 2010). 
 
AZD6610 and diclofenac, used as model substrates in Paper IV, formed acyl 
glucuronides from carboxylic acids. The acyl glucuronides formed from carboxylic 
acids are an important class of the O-glucuronides, since these metabolites are quite 
reactive and may cause toxicity (Williams et al, 1992). Intermolecular reactions with 
nucleophilic compounds include hydrolysis, transacylation with glutathione (Grillo et 
al., 2003) and direct trans-acylation of protein (McGurk et al., 1996), leading to 
proteins which may induce or interfere with an immune response. These reactions are 
in competition with intra-molecular nucleophilic rearrangements, particularly internal 
migration of the acyl moiety resulting in glucuronide isomers (Skordi et al., 2005).  
 
1.3.2.2 CoA conjugation and β-oxidation 
 
Mitochondrial β-oxidation is primarily involved in the oxidation of fatty acids and 
provides energy to cellular processes. The first step in microsomal fatty acid oxidation 
is ω-hydroxylation at the terminus carbon, which takes place in the endoplasmic 
reticulum by CYP4 enzymes and the resulting ω-hydroxy fatty acid is then 
dehydrogenated to a carboxylic acid in the cytosol. Carboxylic acids are converted to 
carboxylic-CoAs for oxidation by the β-oxidation pathway and the chain is shortening 
by removal of two carbon units (Mortensen, 1992; Fer et al., 2008). Noteworthy, the 
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same oxidation pathway has been recognized to be involved in the metabolism of some 
xenobiotics, including the PPAR α/ɣ agonist, AZD6610, studied in Paper IV 
(Hashizume et al., 2002; Kalsotra et al., 2004; Kalsotra and Strobel, 2006; Jin et al., 
2011; Zollinger et al., 2011) 
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1.4 DRUG TRANSPORT 
 
Transporter pharmacology is a rapidly emerging field in drug discovery and 
development with challenges of overlapping substrate and inhibitor specificities across 
transporters. Although more than 400 human transporters have been identified at the 
molecular level, relatively few of these have, to date, been shown to be important in 
drug disposition (Giacomini et al., 2010). Transporters are expressed in several tissues 
including, but not limited to, intestine, brain, liver and kidney. Some transporters are 
tissue specific, whereas others are detected in more than one tissue (Figure 3). 
 
 
1.4.1 Nomenclature 
Membrane transporters are divided into two main superfamilies, ATP-Binding Cassette 
(ABC) (Schinkel and Jonker, 2003) and SoLute Carrier (SLC) (Hediger et al., 2004) 
superfamily. The gene names reflect the superfamilies, e.g. ABCB11 and SLCO1B1, 
whereas some protein names reflect the type of substrate being transported, e.g. BSEP 
(Bile Salt Export Pump) and OATP1B1 (Organic Anion Transporting Polypeptide 
1B1). 
 
 
1.4.2 Function and location 
 
Transporters consist of a number of transmembrane domains and one or more binding 
domain(s) which facilitate the translocations of drugs over the cell membrane. The 
transport is bi-directional and active, enabling transport against a concentration 
gradient. However, many drugs undergo both passive diffusion and active transport. 
The ABC transporters, also referred to as efflux transporters, are ATP-dependent and 
pump the drugs out from the cell. The SLC transporters may work in both direction and 
are driven by electrochemical gradients or gradients of counter-substrates or co-
substrates (Choudhuri and Klaassen, 2006; Endres et al., 2006) 
 
Drug transporters are expressed throughout the body in all tissues and are detected both 
on the apical and basolateral membrane of the cells (Figure 3) (Nishimura and Naito, 
2005; Endres et al., 2006; Hilgendorf et al., 2007; Giacomini et al., 2010). The efflux 
transporters, located on the apical membrane have a protective function. One example 
is the most well known transporter, P-glycoprotein (P-gp, ABCB1/MDR1), which 
efflux the substrates into the gut or into bile and from brain capillary endothelial cells 
into peripheral blood (being a part of the blood-brain barrier), preventing the substrate 
to reach the blood circulation and/or sensitive organs (Figure 3) (Endres et al., 2006). 
The SLC transporters are frequently associated with uptake of compounds from the 
blood into tissue or organs such as liver and kidney or involved in absorption from the 
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gastrointestinal tract or lung tissue into the peripheral circulation. Uptake and efflux 
transporters can co-operate in order to eliminate xenobiotics (Endres et al., 2006). 
 
 
 
 
 
Figure 3. Overview of selected human transport proteins, for drugs and endogenous substances, 
expressed in intestine epithelia, brain capillary endothelial cells, hepatocytes and in the kidney proximal 
tubules (Giacomini et al, 2010) and the presence of P450 and UGT enzymes in the same tissue. After oral 
administration of a drug, both transporters and metabolizing enzymes can take part in the first pass effect 
influencing the bioavailability of the drug (D). The drug (D) and/or the metabolite (M) can leave the body 
via excretion to urine, bile and faeces. 
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1.4.3 Clinical relevant transporters 
 
There are a limited number of transporters that seems to have an impact on drug 
disposition, safety and efficacy. Researches within the academy and pharmacy industry 
as well as regulatory agencies such as, Food and Drug Administration (FDA), have 
formed the International Transporter Consortium (ITC) to draw up” to date” transporter 
guidelines for drug development. The ITC members emphasize the importance of 
dynamic guidelines, which will need to be modified regularly as the research front in 
this area moves forward (Giacomini et al, 2010). The transporters that are currently 
proven to be clinically important are P-gp/MDR1, BCRP, OATP1B1, OATP1B3, 
OCT2, OAT1, OAT3, OCT1 and BSEP (Figure 3) (ITC, European Medicines Agency 
(EMA) draft). 
 
 
1.4.4 Transporter mediated drug-drug interactions 
 
There are several clinical DDIs described in the literature that are believed to be 
transporter mediated. Two examples are the 890% increase of pravastatin AUC when 
co-administrated with cyclosporine and the 157% increase of digoxin AUC when co-
administrated with dronedarone probably due to inhibition of OATPs and P-gp, 
respectively (Neuvonen et al., 2006; US Food and Drug Administration, 2006; Kiser et 
al., 2008). 
 
Clinical DDI studies may not elucidate the molecular mechanism for a certain 
interaction but rather determines required dose adjustments. The mechanism for drug 
interactions are often best studied using in vitro systems in preclinical investigations 
(Giacomini et al, 2010). 
 
 
1.4.5 Polymorphic transporters 
 
Some drug transporters are polymorphic with non-synonymous mutations leading to 
amino acid changes/deletions. These amino acid alterations may affect membrane 
localization, function and capacity of the transporters (Shu et al., 2003; Niemi, 2007). 
Transporters expressed in the liver, such as OATP1B1, OCT1 and BCRP are reported 
to have clinical relevant genetic polymorphisms (Pasanen et al, 2006; Keskitalo et al, 
2009; Zhou et al, 2009) 
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1.5 METABOLISM AND TRANSPORT INTERPLAY 
 
Both transporters and metabolizing enzymes may be involved in the elimination of the 
same drug, which can complicate the evaluation and understanding of drug-drug 
interactions studies in vitro and in vivo. A drug may be: 1) taken up into the hepatocyte 
by uptake transporters, 2) metabolised by phase I and/or phase II enzymes, 3) the parent 
drug and/or the metabolite(s) may be transported back to the blood and/or into bile 
(Figure 3). All these enzymes and transporters are potential sites of DDIs. There are 
many examples of DDIs at the level of hepatic cytochrome P450, but changes in the 
concentration of the drug in the cells or in the circulation can also occur by either 
inhibition or induction of relevant transporter proteins in the liver (Wu and Benet, 
2005; Shitara et al., 2003a). 
 
 
1.5.1 Induction 
 
Enzyme induction generally occurs at the transcriptional level and the most important 
nuclear receptors for regulation of drug metabolizing P450s and transporters are the 
aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) and pregnane 
X receptor (PXR). The transcription of several metabolizing enzyme and transporter 
genes can be increased by the same inducer, caused by ligand binding to one or more 
nuclear receptor(s). The activation of AhR induce CYP1A gene expression, whereas 
CAR and PXR have been reported to induce the same genes by binding to DNA 
response elements belonging to the CYP2B6, CYP2C, CYP3A4, ABCB1 and ABCC2 
genes (Lin, 2006; Xie et al, 2000; Martin et al., 2008; Pal et al., 2011). Further, it is not 
unusual that the ligand binding to the transcription factors are substrates of products of 
the induced gene (autoinduction). 
 
 
1.5.2 Drug-drug interactions 
 
Rifampicin both inhibits OATP uptake transporters and induces P450 enzymes. Zheng 
and co-workers (2009) showed a clinical example where rifampicin interacted with the 
OATP/P450 substrate glyburide. The first intravenous dose of rifampicin increased the 
AUC of glyburide, most likely due to inhibition of OATP, whereas multiple doses of 
rifampicin decreased the AUC of glyburide, probably due to induction of P450 
enzymes. Further, Niemi et al. (2003) showed that repaglinide, a substrate of both 
CYP3A and OATP, gave a 1.4-fold increase in AUC upon co-administration with 
itraconazole (CYP3A inhibitor) and 8.1-fold increase in AUC with gemfibrozil (OATP 
inhibitor).  However, simultaneous inhibition of CYP3A and OATP resulted in a 19-
fold AUC increase of repaglinide, suggesting that enzyme-transporter interplay may 
give rise to synergistic inhibitory effects.  
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1.6 LIVER IN VITRO MODELS 
 
Both in vitro tools and animal experiments are used in preclinical drug development to 
evaluate the pharmacokinetic properties of new drug candidates. In addition, human 
relevant tools are needed to investigate the formation of major drug metabolites, the 
involvement of metabolizing enzymes and transporters in drug disposition as well as 
the potential site of DDIs. Since the liver is the most important organ for drug 
metabolism, in vitro models which reflect functions of the human liver are desired.  
 
 
1.6.1 Identification of drug metabolizing enzymes  
 
To find out if a new drug candidate or its metabolites are substrates of a certain 
metabolizing enzyme, human recombinant P450 and UGT enzymes expressed in e.g. 
Escherichia coli or baculovirus infected cells, can be used to investigate  one enzyme at 
a time (Zhao et al., 1996; Mano et al., 2004). The fraction of the metabolic clearance 
via a certain enzyme is valuable information during drug development and in clinical 
studies to understand the basis for pharmacokinetic variability and sensitivity as a 
victim for drug interactions. Further, in vitro P450 inhibition studies are required to 
evaluate whether a drug candidate may act as a perpetrator and thus pose a risk to affect 
the kinetic profiles of co-administered drugs.  The inhibition of CYP1A2, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6 and CYP3A4 by the drug candidate is routinely tested 
in recombinant human P450s systems (Turpeinen et al., 2006).   
 
 
1.6.2 Identification of drug metabolite profiles 
 
The impact on efficacy and safety of drug metabolites formed and circulating in vivo 
has to be evaluated in human. Comparisons of in vitro metabolite profiles across 
species can provide an early indication if a new drug candidate has a different major 
metabolic pathway in human than in animals used for safety evaluations (Wang et al., 
2010). Therefore, radiolabeled drug candidates are incubated in suspensions of 
cryopreserved hepatocytes prepared from animals and humans to compare the 
metabolite profiles. The standard incubation time is 2 h and the metabolites are 
identified using liquid chromatography-high resolution mass spectrometry (LC/MS). 
However, longer incubation times may be applied when slowly metabolized drugs are 
evaluated. 
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1.6.3 Identification of drug transporter enzymes 
 
To evaluate the contribution of a single uptake transporter in drug or metabolite 
disposition, human embryonic kidney 293 (HEK293) cells over expressing individual 
transporters may be used. The study of efflux transporters is however more difficult. 
First, the drug has to pass the cell membrane (excluding drugs and metabolites with 
poor permeability), then the cells loaded with the drug have to be washed, before the 
efflux can be measured. Therefore, inside-out membrane vesicles prepared from cells 
over expressing a specific transporter are increasingly being used to study the function 
of efflux transporters. In contrast to the cellular systems, the drug interacts directly with 
the efflux transporter in the vesicles without the need to first permeate a cell membrane. 
The kinetics of drug transporter interactions can thus be determined with higher 
accuracy in a vesicle system than in a cellular system (Karlsson et al., 2010). 
Unfortunately, this model is not suitable for lipophilic and highly membrane-permeable 
drugs, which result in high passive uptake into the vesicles, masking the contribution of 
active transport. 
 
 
1.6.4 Hepatic efflux 
 
Human epithelial Caco-2 cells (colorectal adenocarcinoma cells) can be used as a 
model to study hepatic efflux transporter-mediated interactions. Caco-2 cells are 
polarized and express drug efflux transporters such as P-gp, BCRP and MRP2, which 
are also found in the canalicular membrane of hepatocytes. Caco-2 also express uptake 
transporters and to some extent metabolizing enzymes. Confluent monolayer of Caco-2 
cells on filters in transwell plates enables bi-directional transport studies. Co-
administration of two or more drugs acting as substrates or inhibitors of the same 
transporter comprises the basis for transporter-mediated interactions (Choudhuri and 
Klaassen, 2006). However, the inhibitors used to identify the involvement of a specific 
transporter of a drug compound may not be selective and the in vitro concentrations 
used in such experiments are often high. Thus, it cannot be excluded that these 
inhibitors block the function of several other transporter proteins expressed in Caco-2 
cells and thus the information from in vitro experiment, investigating the involvement 
of specific transporters by inhibitors, may not be conclusive (Watanabe et al., 2005; 
Wang et al., 2008).  
 
RNA silencing leading to functional inactivation of the target gene is an attractive 
method for down-regulation of the expression of specific genes. Short interfering RNA 
(siRNA) can mediate strong and specific suppression of gene expression by sequence 
specific cleavage of mRNA, thus blocking the translation into target protein (Watanabe 
et al., 2005; Yue et al., 2009). SiRNA is a valuable tool to investigate the contribution 
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of specific transporters in the transcellular transport of drug molecules and to predict 
potential sites of pharmacokinetic interactions (Darnell et al. 2010 (Paper I)).  
 
 
1.6.5 Hepatic uptake  
 
Although Caco-2 cells can be used as a model to study the hepatic efflux transport 
interactions, the evaluation of uptake activity of important hepatic drug transporter such 
as OATP1B1, OATP1B3 and OCT1 requires more liver like models or cell lines over 
expressing these enzymes (Hilgendorf et al., 2007). Different hepatic in vitro assays 
have been established to evaluate the uptake kinetic of drugs and the biliary efflux as 
well as the loss of drugs from the incubation medium.  
 
Primary hepatocytes express a complete set of metabolizing enzymes and transporters 
involved in hepatic drug clearance and are recognized to best predict relevant in vivo 
clearance parameters. However, an extensive decrease in OATP1B1/1B3 activity, 
already after 6 h, has been reported in plated fresh human hepatocytes (Ulvestad et al. 
2011). Therefore, it is important to perform uptake studies within a few hours after cell 
isolation.  
 
Alternatively, sandwich cultured human hepatocyte can be used if longer incubation 
times are required. The culture of hepatocytes in a sandwich format between collagen 
and matrigel allows the formation of intact canalicular networks and polarized 
excretory function (Bi et al., 2006; Lee et al., 2010). Further, the transporter protein 
levels are maintained for several days and both uptake and biliary efflux can be 
accessed through modulation of calcium ions (Hoffmaster et al., 2004; Bi et al., 2006; 
Lee et al., 2010).  
 
However, the use of fresh human hepatocytes is limited by the availability and quality. 
Fortunately, the activities of important hepatic drug uptake transporters OATP1B1/1B3 
and to some extent also OCT1 have been reported to be present in cryopreserved 
human hepatocytes, which is more convenient to use than fresh human hepatocytes 
(Soars et al., 2009; Shitara et al 2003b; Umehara et al., 2007).  
 
 
1.6.6 Predictions of hepatic clearance  
 
The pharmaceutical industry aims to develop metabolic stable drugs, which in many 
cases leads to a shift in drug elimination processes from metabolic, towards transporter-
mediated drug excretion. Today, the clearance of up to 20% new drug candidates is 
under-predicted, probably due to an active uptake of drugs into the hepatocyte (Soars et 
al., 2009). The clearance of new drug candidates is routinely assessed using 
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suspensions of cryopreserved human hepatocytes, by measuring the disappearance of 
the parent drug in a mixture of cells and medium. The transporter processes are not 
properly evaluated in such assays and metabolic stable drugs are predicted to have 
almost no clearance in vivo. However, the in vivo clearance can be high if the drug is a 
substrate of hepatic drug transporters, which can enable fast elimination (e.g. via 
excretion to bile). Soars and co-worker (2009) discuss two relatively new methods 
which enables the measurement of hepatic uptake. The cells are centrifuged in 
Eppendorf tubes or through a layer of oil and the loss of drug from the media is 
measured in the supernatant. In addition, the appearance of the drug in the cells can be 
assessed. These new in vitro methods, which include the hepatic drug uptake processes, 
have improved the in vitro-in vivo drug clearance correlations. In addition, the method 
can also be used to assess potential DDIs in the hepatic uptake by applying inhibitors to 
the cell incubations (Soars et al., 2009). 
 
 
1.6.7 Induction 
 
Metabolizing enzymes and transporters can be induced by xenobiotics and may cause 
loss of effect due to sub-therapeutic concentrations or unwanted side-effects due to 
changed concentrations of the drug or metabolite in plasma and tissue. Reporter gene 
assays, immortalized cell lines and cultured primary human hepatocytes have been used 
to evaluate the induction of P450 enzymes (e.g. CYP1A, CYP2B6, CYP2C and 
CYP3A4) by new drug candidates (Abadie-Viollon et al. 2010). Recently, the human 
hepatoma cell line, HepaRG, has been documented to provide reliable prediction of 
P450 drug induction in vivo in human (Kanebratt and Andersson, 2008a) and can be 
used as a new model to evaluate the P450 induction potential of drug candidates.  
 
 
1.6.8 Tissue like in vitro model of the human liver  
 
As described above, primary human hepatocytes are used in most liver in vitro studies 
in drug development, since they are able to perform the full range of known in vivo 
drug biotransformation pathways and retain many of the uptake and efflux functions of 
liver cells (De Bartolo et al., 2006). However, a high variability of P450 and transporter 
activities between different donors is usually observed, which can be caused by both 
inter-donor differences and variation in cell quality (Tostões et al., 2011). The majority 
of liver cell culture studies have been performed using conventional two-dimensional 
(2D) cell culture systems, which are convenient and easy to use (Goral et al., 2011). 
Nevertheless, both fresh and cryopreserved hepatocytes have a rapid loss of liver 
specific functions over time in culture, which may partly be explained by the rupture of 
the 3D structure of the tissue, low oxygen supply and the absent of shear stress from the 
blood-flow (Tilles et al., 2001; Rodríguez-Antona et al., 2002; Wang et al., 2010; Vinci 
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et al., 2011). Recently, unexpected plasticity of mature hepatocytes to dedifferentiate 
into progenitor cells, when cultured in 2D, was reported by Chen and co-workers 
(2012). The study revealed that hepatocytes rapidly transformed into liver progenitor 
cells within one week through a transient oval cell-like stage when maintained in 2D, 
thus explaining the loss of liver specific functions (Chen et al., 2012). 
 
Several attempts to provide physiologically relevant conditions that preserve in vivo-
like phenotype and biological activity of hepatocytes have been published. Microfluidic 
platforms, co-cultures, flow based hollow fiber bioreactors and spheroids have been 
used to mimic the situation in the liver (De Bartolo et al., 2006; Dittrich et al., 2006; 
Khetani and Bhatia, 2008; De Bartolo et al., 2009; Schmelzer et al., 2009; Leite et al., 
2011; Prot et al., 2011). Some of these new culturing approaches enable a 3D structure, 
cell-cell contact and also a constant medium flow and oxygen supply that all are 
important for the intracellular functions and the maintenance of cell polarity (Tilles et 
al., 2001; Zeilinger et al., 2004; Schmelzer et al., 2009; Vinci et al., 2011). It has 
previously been shown that fresh human hepatocytes can retain their liver specific 
functions such as urea and albumin synthesis, glucose metabolism and P450 activities 
for at least two weeks in 3D cultures (Zeilinger et al., 2002; Zeilinger et al., 2011 
(Paper II)).  
 
The bioreactor technology enables prolonged incubation times and may enable the 
prediction of clearance, metabolite profiles as well as interaction profiles of metabolites 
formed from slowly metabolized drugs, which are not detectable in other human in 
vitro systems. Thus, the bioreactor can be used to avoid selection of drug candidates 
with human unique metabolites, which are not formed in animals. Such metabolites 
may be formed and identified after prolonged incubation times in human in vitro 
systems before entering clinical studies. 
 
Another important application of the bioreactor for the pharmaceutical industry is to 
predict human hepatic toxicity, which is not always revealed by the preclinical models 
used today (Leite et al., 2011) 
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2 AIMS 
 
 
The overall research aim for my thesis was to evaluate the use of several in vitro 
techniques to predict drug metabolism, drug transport and drug-drug interactions in 
vivo. Special attention was directed towards long-term cultures in a dynamic three-
dimensional bioreactor culture system using HepaRG cells and primary human 
hepatocytes.  
 
The following studies were performed: 
 
 Knockdown of drug efflux transporters in Caco-2 cells using short hairpin RNA 
to identify the involvement of efflux transporters in drug transport and to 
predict potential sites of transporter-mediated pharmacokinetic interactions. 
 
 Measurement of P450 activities over time in fresh human hepatocytes cultured 
in a dynamic 3D bioreactor. 
 
 Investigation of the maintenance, induction and inhibition of P450 activities in 
HepaRG cells cultured in a dynamic 3D bioreactor compared to in vivo data. 
 
 Evaluation of the major human in vivo metabolic pathways of two model 
substrates in HepaRG cells, fresh and cryopreserved human hepatocytes using 
cell suspension and a dynamic 3D bioreactor system. 
 
 Investigation of the functionality of OATP1B1 in fresh human hepatocytes and 
HepaRG cells using suspension and a dynamic 3D bioreactor system. 
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3 METHODOLOGICAL CONSIDERATIONS 
 
 
3.1 TRANSPORT STUDIES IN CACO-2 KNOCKDOWN CELLS  
 
Usually, the detection of transporter-mediated interactions is achieved by co-
administration of a compound of interest with other substrates or inhibitors that bind to 
and/or interact with the same transporter (Choudhuri and Klaassen, 2006). In Paper I, 
RNA interference was used to knockdown efflux transporters in Caco-2 cells to detect 
transporters responsible for the efflux of drug substances that may be involved in drug-
drug interactions in vivo. 
 
 
3.1.1 siRNA knockdown 
 
RNA interference is a natural cellular process that effects post-transcriptional gene 
silencing in eukaryotic cells. SiRNA molecules are the key intermediaries in this 
process which can inhibit or silence the expression of any given target gene by 
degradation of mRNA in a sequence-specific manner. SiRNA can be exogenously 
delivered to cells as synthetic duplexes or endogenously expressed as short hairpin 
RNA (shRNA), following transfection of plasmid or viral siRNA expression vector 
constructs. SiRNA causes only transient knockdown of target genes, whereas stable 
knockdown is established by using shRNA (Celius et al., 2004; Yue et al., 2009). 
 
In Paper I, Caco-2 cells were transfected with Lentivirus plasmid vectors containing 
shRNA inserts targeting human P-gp (GenBank accession number NM_000927) or 
MRP2 (GenBank accession number NM_000392) genes (Sigma-Aldrich, St. Louis, 
MO) at Absorption Systems LP (Exton, Pennsylvania) to establish cell lines with stable 
knockdown of transporters (Figure 4A). As a transduction control, parental Caco-2 
cells were also transduced with a lentivirus plasmid vector containing shRNA that does 
not match any known human genes (Sigma-Aldrich), and the transduction procedures 
were identical to those used to establish P-gp and MRP2 knockdown. 
 
The P-gp and MRP2 mRNA expression, protein expression and transporter activity 
using probe substrates (Table 2) were compared in vector control cells and P-gp and 
MRP2 knockdown cells. In addition, the mRNA expression of several transporters, 
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metabolizing enzymes and transcription factors were measured in the three different 
cell lines to detect nonspecific effects, which can depend on both knockdown of 
nontarget mRNA (Jackson et al. 2006) or compensatory effects causing up-regulation 
of other genes (Chen et al., 2005). The only changes observed were the 2-fold higher 
mRNA expression of UGT2B7 in P-gp knockdown cells and of transthyretin in MRP2 
knockdown cells compared to control vector cells (Darnell et al 2010 (Paper I)). These 
nonspecific effects are not likely to interfere with the transport of ximelagatran and its 
metabolites investigated in Paper I. 
 
 
3.1.2 Bi-directional transport studies 
 
Caco-2 cells cultured on filters in transwell plates form a monolayer with tight 
junctions which separate the apical and basolatera chamber (Figure 4B). This system 
enables bi-directional transport studies. The knockdown of efflux transporters mimics 
the situation in vivo, when the efflux transport of the drug of interest is reduced duo to 
co-administration of a drug, which is a substrate or inhibitor of the same transporter.  
 
 
 
 
Figure 4. (A) Stable knockdown of P-gp and MRP2 in Caco-2 cells 
using shRNA. (B) Culture of Caco-2 cells in transwell plates to 
study the bi-directional transport of drugs. 
Filter
Basolateral chamber
Apical chamber
Monolayer
B
3 Author | 00 Month Year Set area descrip tor | Sub level 1
ATPATP
MRP2
ATP
P-GP
ATP
P-GP MRP2
DNA
MDR1/MRP2 mRNA
shRNA
siRNA Degradation of
MDR1/MRP2 mRNA
Blocked translation
Caco-2 with stable
MDR1/MRP2 knockdown
Transfection
Decreased efflux of P-gp/MRP2 substrates
Anti-MDR1/MRP2 shRNA
encoding viral vector
A
   25 
 
3.2 PRIMARY CELLS AND CELL LINES  
 
3.2.1 Fresh human hepatocytes 
 
Primary human liver cells used in Paper IV and V were isolated from the liver tissue 
remained after partial resection by qualified medical staff following ethical and 
institutional guidelines at Karolinska University Hospital (Huddinge, Sweden). The 
isolated fresh human hepatocytes were transported from Karolinska University Hospital 
to AstraZeneca R&D (Mölndal, Sweden) in a cold package at the same day as tissue 
surgery and cell isolation.  
 
Primary human liver cells in Paper II were isolated from donor organs excluded from 
transplantation due to organ injury or from liver tissue remained after partial resection 
at the Charité University Hospital (Berlin, Germany). Cells were isolated from whole 
organs or tissue pieces in accordance with European and national regulations and with 
the approval by the local ethics committée. 
 
It is well known that hepatocytes suffer a rapid loss of liver specific functions after cell 
isolation. Therefore, the cell suspension experiments, in Paper IV and V, were 
performed the same day as the tissue surgery and hepatocyte isolation to evaluate the 
functional properties of the hepatocytes shortly after cell isolation. In addition, the 
hepatocytes, in Paper II, IV and V, were inoculated into the bioreactor the same day as 
tissue removal and cell isolation to attain as good quality of the hepatocytes as possible. 
 
 
3.2.2 Cryopreserved human hepatocytes 
 
A considerable improvement of hepatocyte cryopreservation protocols has been 
achieved during recent years allowing storage, transport and scheduling of experiments 
(Li et al., 2008). In Paper, IV and V, pooled cryopreserved human hepatocytes from 
three different batches (IRK, UMJ and PHL), each containing hepatocytes from ten 
donors, were used. Cryopreservation and pooling of human hepatocytes were 
conducted at Celsis In Vitro Technologies (Brussels, Belgium) using a controlled 
freezing protocol according to in-house procedures. The P450s, UGTs and drug 
transporters activities were well characterized and 10 different donors were selected to 
be included in the same batch to receive a good balance of drug metabolizing enzyme 
and transporter activities. Thus, avoiding the drawbacks of high inter-donor variability 
observed when using primary human hepatocyte from few donors.  
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3.2.3 HepaRG cells 
 
The HepaRG cells were developed from a human hepatocellular carcinoma and were 
purchased from Biopredic International (Rennes, France). In vitro, proliferating 
HepaRG cells differentiate toward hepatocyte-like and biliary-like cells at confluence. 
However, maximum cell differentiation is reached after two weeks with 2% DMSO 
exposure. Hepatocyte-like cells exhibit a phenotype close to that of human hepatocytes, 
with functional bile canaliculus-like structures as evidenced by fluorescein excretion 
(Cerec et al., 2007). In addition, HepaRG cells exhibit important functions for drug 
metabolism and disposition such as P450, UGT and transporter activities (Aninat et al., 
2006; Le Vee et al., 2006; Kanebratt and Andersson, 2008a; Hart et al., 2010).  If 
hepatocyte-like cells are selectively isolated and cultured at high cell density, they 
proliferate and preserve their differentiation status. However, when plated at low 
density, they transdifferentiate into hepatocytic and biliary lineages through a bipotent 
progenitor (Cerec et al., 2007).  
 
In Paper III, the cells were first proliferated in 2D flasks to gain sufficient cells (80 x 
10
6
 cells) for culture in a bioreactor with a cell compartment of 2 ml. Then the HepaRG 
cells were further proliferated in the bioreactor to reach confluence followed by two 
weeks differentiation with DMSO. The DMSO containing medium was washed out and 
the experimental phase was started nine weeks after the HepaRG cells were received 
from Biopredic. To shorten the experimental period, cryopreserved differentiated 
HepaRG cells were applied in Paper IV and V. The experiments could start already 2 
days after inoculation.  A two layer bioreactor with a smaller cell compartment of 0.5 
mL was applied, thus reduced the number of cells needed. 
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3.3 3D CULTURE SYSTEM 
 
3.3.1 Bioreactor prototypes 
 
The bioreactor consists of three interwoven capillary bundles, each made of multiple 
hollow fiber capillaries for counter-current medium perfusion (red and blue) and gas 
supply (yellow), which allows decentralized nutrient and oxygen/CO2 exchange with 
low gradients (Figure 5A, B). 
 
 
 
 
Figure 5. (A) Smallest capillary unit with two medium capillaries that are independently perfused (red 
and blue) and one gas capillary (yellow); cells are cultured within the extra-capillary space (cell 
compartment). (B) The hollow fiber capillaries. (C) Down-scaling of the clinical-scale bioreactor 
prototype with a cell compartment volume of 800 mL resulting in a cell compartment volume of 8 mL 
and a further down-scaled model with a cell compartment volume of 2 mL. From Zeilinger et al., 2011, 
Figure 1 (Paper II). 
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In Paper II, the three-dimensional multicompartment hollow fiber bioreactor proven to 
function as a clinical extracorporeal liver support system was scaled down in two steps 
from a cell compartment of 800 mL to 8 mL and 2 mL (Figure 5C, 6). A smaller 
number of fresh human hepatocytes or HepaRG cells are required in bioreactors with 
reduced cell compartments, increasing the utility of bioreactors as a tool in preclinical 
studies. 
 
In Paper III, a 2 ml bioreactor was used and in Paper IV and V, an even smaller 
bioreactor prototype was used with a cell compartment of 0.5 ml made of only two 
layers of capillaries with oxygenation and medium capillaries in the same layer. This 
prototype was developed to increase the throughput of experiment and enabling 
experiments in three parallel bioreactors in the same perfusion system.  
 
 
 
 
Figure 6. The photograph shows the clinical-scale 800 mL bioreactor (left) and two laboratory-scale 
variants with a cell compartment volume of 8 mL (middle) or 2 mL (right). The scale bar corresponds to 
10 cm. In the background, the perfusion device for bioreactor operation can be seen. The device disposes 
of pump heads for medium recirculation and medium substitution with automated pressure control, an 
electronically regulated heating unit, rotameters for regulation of the flow rates for air, oxygen, CO2, and 
for the total gas mixture, and a display for digital monitoring and regulation of system parameters. From 
Zeilinger et al., 2011, Figure 2 (Paper II). 
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3.3.2 Perfusion system 
 
The bioreactors are operated by means of an electronically controlled perfusion device 
allowing two to three bioreactors to be run in parallel. Temperature, medium feed and 
medium recirculation rates are monitored and regulated via a connected computer. A 
valve-controlled gas mix unit is used for air/oxygen/CO2 supply. Bioreactors and tubing 
are sterilized before use and rinsed with phosphate buffered saline and medium before 
cell inoculation. The sampling port enables substance injection and sampling (Figure 
7).  
 
 
Figure 7. Bioreactor perfusion system with sampling port and tubing for medium recirculation, feeding 
and outflow. From Darnell et al., Figure 1, (Paper IV). 
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3.3.3 Bioreactor culture 
 
In Paper II, IV and V, the medium used for the long term culture of fresh human 
hepatocyte was enrichment with amino acids, free fatty acids and trace elements. 
Medium containing 5-10 times higher amino acid concentrations compared to most 
standard media are superior for the maintenance of cell survival, preserving cellular 
protein levels and liver-specific functions (Jauregui et al., 1986; Sawada et al., 1987). 
Higher levels of amino acids have been suggested to aid in the recovery of hepatocytes 
following collagenase digestion, arrest lysosomal protein degradation (Jauregui et al., 
1988), and inhibit RNA degradation while stabilizing the activity of some liver-specific 
enzymes (Balavoine et al., 1992; Lee et al., 1992). 
 
In Paper II, the hepatic functionality and cell quality were assessed during the culture 
period by measuring the daily production of glucose, urea and albumin and the release 
of aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) in the 
recirculating and outflow medium. The production of urea, glucose and albumin are 
important functions of the liver in vivo and the detection of these products in the 
bioreactor medium indicate maintenance of hepatocyte functions. Further, the leakage 
of AST and LDH into the culture medium indicates hepatocellular toxicity or tissue 
break down. AST and LDH are normally high in the beginning of the culture due to 
stress after cell isolation, but a low level is usually obtained within a few days. 
 
 
3.4 DRUG-DRUG INTERACTIONS IN HEPARG CELLS CULTURED IN 
BIOREACTOR  
 
In Paper III, the P450 activity over time was accessed in HepaRG cells cultured in 
bioreactors by measuring metabolites formed from a cocktail of P450 probe substrates 
including phenacetin, midazolam, bupropion and diclofenac (Table 2). Further, to 
evaluate the prediction of DDIs, the effect of the model P450 inducer rifampicin and 
inhibitor ketoconazole were sequentially investigated in the same bioreactor culture 
(Table 2). The change in metabolite formation rates was calculated to enable the 
comparison with in vivo data from the literature. 
 
 
3.5 METABOLITE PROFILING 
 
The metabolite profiles of two model substrates were evaluated in Paper IV in 
cryopreserved human hepatocyte, fresh human hepatocyte and in HepaRG cell 
suspensions on day 0 and in bioreactors on culture day 5 and 6. The same procedure as 
used within the pharmaceutical industry was conducted for metabolite profiling in 
suspension. The suspension experiment was performed in 96-well plates and 
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metabolites were analyzed from both the medium and lysed cells. However, only the 
medium was analysed in the bioreactor experiments. The levels of metabolites retained 
in the cells cultured in the bioreactor were not analyzed and the metabolite profile may 
be different from that detected in the medium. In future studies, a centrifugation step 
could be included in the suspension experiments to facilitate the measurement of 
metabolites in the medium, which would be more comparable to the bioreactor 
experiments. 
 
 
3.6 TRANSPORTER UPTAKE ACTIVITY 
 
In Paper V, the OATP1B1 activity was evaluated in cell suspension and in bioreactor 
using the same cells as in Paper IV. To study a transporter-mediated drug uptake in cell 
suspension, either the loss of drug from the medium or the accumulation of drug in the 
cells can be measured. In this study, both the intracellular accumulation and the 
concentration in the medium were assessed in the same experiment at different time 
points. Several washing and centrifugation steps were performed to enable the 
separation of the cells from the medium. In the bioreactor, the cells and the medium are 
already separated and medium samples were easily removed via the sampling port to 
measure the loss from medium (Figure 7). To assess the OATP1B1-mediated uptake of 
estradiol-17β-D-glucuronide (E17βG) and atorvastatin (Table 2), the experiments were 
performed with and without 30 µM estrone-3-sulfate (E3S), which selectively inhibit 
OATP1B1-mediated uptake with little effect on OATP1B3 (Ishiguro et al., 2006).  
 
Table 2. In vitro probe substrates, inhibitors and inducers of metabolizing enzymes and transporters. 
 
 
 
3.7 LC/MS/MS ANALYSIS 
 
In Paper I, II, III and V LC/MS/MS analysis was conducted to measure the 
concentration of substrates of transporters and metabolizing enzymes as well as the 
formed metabolites in suspensions, 2D and 3D cultures. Standard curves with known 
concentration of the substrates and metabolites were included in each run and used for 
Compound Function Enzyme Metabolite Conc. [µM] Paper
Midazolam Substrate CYP3A 1'-hydroxymidazolam 3 II, III
Bupropion Substrate CYP2B6 Hydroxybupropion 100 II, III
Phenacetin Substrate CYP1A1/2 Paracetamol 26 II, III
Diclofenac Substrate CYP2C9 4'-hydroxydiclofenac 9 II, III
Diclofenac Substrate UGT2B7/1A3/1A9 Diclofenac acyl glucuronide 10 IV
Digoxin Substrate P-gp 10 I
Bromosulfophthalein Substrate MRP2 0.027 I
Atorvastatin Substrate OATP1B1/CYP3A4 Hydroxyatorvastatin 5 V
E17βG Substrate OATP1B1/1B3 1 V
Ketoconazole Inhibitor CYP3A4 3 III
Estrone-3-sulfate Inhibitor OATP1B1 30 V
Rifampicin Inducer CYP3A4/2B6/2C 20 III
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quantification. Ximelagatran, hydroxyl-melagatran, ethyl-melagatran and melagatran 
and the co-eluted respective isotope-labeled internal standards were measured in the 
same injection. Moreover, the P450 cocktail metabolites, 1’-hydroxymidazolam, 
hydroxybupropion, paracetamol and 4’-hydroxydiclofenac, were analyzed at the same 
time in one injection and the same procedure was used for atorvastatin and its 
metabolites. However, different sample dilutions were required to measure both the 
substrate and the metabolites in the linear range of the standard curve. 
 
 
3.8 Q-TOF LC/MS ANALYSIS 
 
In Paper IV, the metabolite profiles of two model substrates were assessed using Q-ToF 
LC/MS analysis. The instrument enables the detection of several protonated molecules 
in the same injection, with a mass accuracy up to four decimals. Radiolabeled 
substrates were used to facilitate the quantification of the formed metabolites. Detection 
of metabolites was based on the full-scan MS acquisition, corresponding retention 
times for the MS peak and a peak in the radiochromatogram and the absence of the 
potential metabolite peak in the MS chromatogram of the 0 min sample. To facilitate 
identification of metabolite M6 of AZD6610, MS and retention times were compared 
to the authentic standard. 
 
Some metabolites co-eluted with other metabolites and could not be separated in the 
radiochromatogram. To estimate the contribution of each metabolite in %, the MS peak 
area in the extracted ion chromatogram for the respective protonated molecule was 
used. The calculation of metabolite proportions in the radiochromatographic peak is 
based on the assumption that the MS responses of all metabolites are equal. While the 
MS response is in fact unknown for all metabolites, the proportions calculated should 
be regarded as estimates, but nonetheless useful in the comparison of metabolite 
profiles between the different cell systems investigated. 
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4 RESULTS AND DISCUSSION 
 
 
4.1 PAPER I - PREDICTION OF HEPATIC TRANSPORTER INTERACTION 
IN VIVO 
 
The human in vivo interaction between ximelagtran and erythromycin was suggested to 
be mediated by inhibition of hepatic efflux transporters (Figure 8A) (Eriksson et al., 
2006). In Paper I, Caco-2 cells were used as a model to study drug efflux transporters 
expressed both in the intestine and in the liver. Stable knockdown of P-gp or MRP2 in 
Caco-2 cells were used to evaluate the involvement of these drug efflux transporters in 
the disposition of ximelagatran and its metabolites.  
 
In the Caco-2 cell monolayers, ximelagatran was metabolized to its intermediate 
metabolites, hydroxy-melagatran and ethyl-melagatran, and its active end product 
melagatran. The appearance rates of ximelagatran, hydroxyl-melagatran and 
melagatran on the basolateral side (Apical-to-Basolateral direction) were significant 
higher (p < 0.01) in P-gp knockdown cells compared to control vector cells and MRP2 
knockdown cells (Figure 8B). In addition, the accumulated amount of the metabolites 
was highest in the P-gp knockdown cells. The in vitro results mimic the effects 
observed in vivo, where the plasma concentrations (“basolateral/blood side”) of 
melagatran, hydroxy-melagatran and ximelagatran were higher after ximelagatran was 
co-administrated with the P-gp inhibitor erythromycin compared to administration of 
ximelagatran alone (Eriksson et al., 2006).  
 
Thus, the results indicated a clear involvement of P-gp but not of MRP2 in the efflux of 
ximelagatran, hydroxy-melagatran and melagatran. P-gp-mediated efflux can therefore 
be concluded to be important for the biliary secretion of ximelagatran and its 
metabolites. However, this study does not rule out the possibility that other hepatic 
transporters, e.g., breast cancer resistance protein, bile salt export pump, and multidrug 
and toxic extrusion 1 may be of importance in the disposition of ximelagatran and its 
metabolites. 
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Figure 8. (A) The figure shows the hepatic clearance of ximelagatran (ximel.) and its metabolites in vivo 
via metabolism and secretion into bile  and (B) a higher appearance rate of ximelagatran and the 
metabolites on the basolateral (blood) side due to less efflux on the apical (bile) side in P-gp knockdown 
Caco-2 cells. Each bar represents mean ± S.D.; n = 3; **, p < 0.01; ***, p < 0.001. From Darnell et al., 
2010, Figure 2 and 7B (Paper I). 
 
Results from in vitro and in vivo studies may not easily identify which enzymes or 
transporters that cause a specific interaction by another drug due to the plethora of 
possible interactions (Choudhuri and Klaassen, 2006). Thus, a more specific strategy, 
where the target enzyme or transporter have been specifically knocked down or 
knocked out in vitro or in animals may be applied or, where possible, studies in healthy 
volunteers with changed activity due to polymorphism of a specific enzyme or 
transporter can be performed (Schinkel et al., 1995; Pasanen et al, 2006; Yue et al., 
2009).  
 
The siRNA gene silencing technique, used in this study, has a great potential in 
transport-mediated DDIs studies for elucidating the function of specific transporters in 
drug disposition.  
  
Ximel. Hydroxy-mel. Melagatran
0.0
0.5
1.0
1.5
2.0
2.5
3.0 Vector Control
P-gp knockdow n
MRP2 knockdow n
***
***
**
[p
m
o
l/
m
in
]
Bile
P-gp
P-gp
MRP2
MRP2
ximel. (X)
M H
E
X
ximel. (X) melagatran (M)
hydroxy-mel. (H)
ethyl-mel. (E)
Blood
A B
   35 
 
  
 36 
 
 
4.2 PAPER II - MAINTENANCE OF HEPATIC FUNCTIONS IN 
BIOREACTOR CULTURES  
 
In Paper II, a three-dimensional multicompartment hollow fiber bioreactor proven to 
function as a clinical extracorporeal liver support system was scaled down in two steps 
from 800 mL to 8 mL and 2 mL bioreactors. The fresh human hepatocytes showed 
maintained and comparable liver specific functions, such as glucose and urea 
production, over 2 weeks, when cultured in the three different bioreactor prototypes 
(Figure 9A).  
 
In addition, the 2 ml bioreactor preserved the activity of major drug metabolizing P450 
enzymes up to 23 days (Figure 9B). A P450 substrate cocktail was injected to the 
bioreactor medium and the initial formation rates of paracetamol (CYP1A1/2), 
4-hydroxydiclofenac (CYP2C9), and 1’-hydroxymidazolam (CYP3A4) were 
maintained at 43%, 8%, and 35%, respectively, in the late culture phase (day 10-23) as 
compared to values from the early culture time (day 3-5). Metabolism rates varied 
between cell preparations from different donors, which probably reflect human 
variation in drug metabolism due to human phenotypes and/or genotypes as well as 
differences in the quality of liver tissue and cells after isolation (Goyak et al., 2008; 
LeCluyse, 2001).  
 
Moreover, hepatocytes and nonparenchymal cells formed tissue-like structures between 
the capillary fibers in the small-scale bioreactor. Biliary cells characterized by 
cytokeratin (CK) 19 immunoreactivity formed channel-like structures that were similar 
in size to those found in intact liver tissue (Figure 9C). Further, the localization and 
distribution of hepatic efflux transporter proteins, such as MRP2 and P-gp/MDR1, to 
one side of the plasma membrane, revealed that the hepatocytes were polarized in the 
bioreactor (Figure 9C). Furthermore, the P-gp/MDR1 and MRP2-positive sides of the 
hepatocytes were facing each other, thus forming bile canaliculi-like structures similar 
to those found in the human liver tissue used as a control (Figure 9C). The finding of 
hepatocytes after two weeks culture in 3D (Paper II), is in sharp contrast to the total 
lack of hepatocytes, due to dedifferentiation into liver-derived progenitor cells, after 
two weeks culture of primary rat hepatocytes in 2D (Chen et al., 2012). 
 
Many new drug candidates have been selected on the basis to be slowly metabolized by 
the liver for a suitable pharmacokinetic profile. However, the experimental models 
available today do not function over a period sufficient to be able to properly 
investigate critical metabolic parameters and toxicity and do not provide the complexity 
of the liver tissue. The preserved liver specific functions, the liver-like tissue and the 
reduced number of cells required for the small scale 2 ml bioreactor, evaluated in this 
study, open up for new and useful application within pharmaceutical research. The 
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results suggest that the system could be used for studies requiring long-term 
performance of cultures, for example, to study kinetic profiles, slowly metabolized 
drugs, DDIs, induction of drug metabolism, and toxicity. 
 
 
 
Figure 9. The figure shows (A) the retained urea production and glucose production/uptake in the 2 mL, 
8 mL and 800 mL bioreactors and (B) the maintained CYP1A1/2, CYP2C9 and CYP3A4 activities in the 
2 mL bioreactor with fresh human liver cells. In addition, (C) the immunohistochemical characterization 
of fresh human liver cells cultivated in the 2 mL bioreactor over 2 weeks (C, right lane) showed polarized 
cells with hepatic efflux transporters MRP2 and P-gp in the cell membrane as well as biliary cells (CK19 
positive) and Kupffer cells (CD68 positive). Staining of intact human liver is shown for control (C, left 
lane). Magnification: 200-fold (bioreactor culture, CK19) or 400-fold. From Zeilinger et al., 2011, Figure 
3, 4 and 5 (Paper II). 
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4.3 PAPER III - PREDICTION OF P450 INDUCTION AND INHIBITION 
USING BIOREACTOR CULTURED HEPARG CELLS  
 
To evaluate an alternative cell source to fresh human hepatocytes for bioreactor culture, 
the stability of P450 activity and prediction of in vivo relevant DDIs were investigated 
in HepaRG cells cultured in the 2 ml bioreactor. We showed that the CYP1A1/2, 
CYP2C9, CYP2B6, and CYP3A4 activities were maintained over several weeks by 
measuring the formation of paracetamol, 4’-hydroxydiclofenac, hydroxybupropion and 
1’-hydroxymidazolam from a cocktail of P450 probe substrate (Table 2).  
 
Further, the co-administration of ketoconazole with midazolam reduced the CYP3A4 
activity by 69% in HepaRG cells cultured in the bioreactor (Figure 10A), which 
reflected well the 85% reduction of midazolam clearance in human when  
 
 
 
Figure 10. The inhibition of CYP3A4 activity (A) in bioreactor cultured HepaRG cells, before (solid 
line) and during (dotted line) ketoconazole treatment and  the induction of CYP3A4 (B) and CYP2B6 (C) 
activities in bioreactor cultured HepaRG cells before (solid line) and directly after (dotted line) rifampicin 
treatment. Results are given as means ± S.D, n = 3 bioreactors. Immunohistochemical staining (brown) in 
HepaRG bioreactor tissue showed bile canaliculi-like structures, where both P-gp (D) and MRP2 (E) 
were located to one side of the hepatocyte-like cells. The metabolic enzyme CYP3A4 was also present 
(F). The distribution of the HepaRG cells between two capillaries is shown in D. From Darnell et al., 
2011, Figures 3, 7 and 8 (Paper III). 
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co-administrated with ketoconazole (Tsunoda et al., 1999; Tham et al., 2006; Yong et 
al., 2008; Krishna et al., 2009).  
 
Furthermore, the 6-fold increases of CYP3A4 and CYP2B6 activities (Figure 10B, C; 
Paper III) after 60 h treatment with the P450 model inducer rifampicin were within the 
induction range observed in vivo in human, where rifampicin increased midazolam 
clearance (CYP3A) by 1.4 to 7.4-fold (Gorski et al., 2004) and the hydroxybupropion 
formation rates (CYP2B6) by 3 to 5-fold (Kharasch et al., 2008). A larger variation in 
the induction range (0 to 21-fold) of CYP3A and CYP2B6 was reported in 2D cultured 
primary human hepatocytes (Abadie-Viollon et al. 2010) compared to in vivo and 
HepaRG cells cultured in 3D (Paper III). Thus, the range of CYP3A and CYP2B6 
induction in vivo in human was better represented by HepaRG cells in bioreactor 
culture than by human hepatocytes in 2D cultures. The larger variation in the induction 
response observed in 2D cultured hepatocytes may be caused by variation in cell 
quality and the erratic loss of liver-specific functions resulting in low basal levels of 
P450 enzymes before exposing the cells to potential inducers (Luo et al., 2002).  
 
Confluent HepaRG cells are known to differentiate into both hepatocyte-like and 
biliary-like cells (Aninat et al., 2006; Guillouzo et al., 2007) , which was clearly shown 
also in the bioreactor where  tissue-like cell aggregations between the capillaries in the 
bioreactor contained both cell types (Paper III). The hepatocyte-like cells were 
polarized as revealed by the location of the transporter proteins P-gp and MRP2 to one 
side of the membrane. The P-gp and MRP2-positive sides of the cells were also facing 
each other (Figure 10D, E), which resembles the histology of the primary human 
hepatocyte cultured in the same bioreactor prototype described in Paper II as well as the 
situation in vivo. In addition, CYP3A4 was found to be expressed in the hepatocyte-like 
cells (Figure 10F) and strand-like formations of CK19-positive cells indicated the 
formation of biliary structures (Darnel et al., 2011 (Paper III)). 
 
The HepaRG cells have previously been shown to maintain P450 activities in 2D 
cultures for several weeks (Jossé et al., 2008; Antherieu et al., 2010). In addition, the 
HepaRG cells have been documented to provide reliable prediction of P450 drug 
induction and drug clearance in vivo in human (Kanebratt and Andersson, 2008a; 
Zanelli et al., 2012). In this study, we showed that HepaRG cells cultured in 3D also 
have a stable P450 activity over several weeks and that the induction and inhibition of 
P450 activities predicted well the magnitude of changes observed in vivo (Gorski et al., 
2004, Kharasch et al., 2008). In addition, polarity of transporter expression and 
formation of tissue-like structures including bile canaliculi were demonstrated by 
immunohistochemistry. 
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The long-lasting bioreactor system using HepaRG cells thus provides a promising and 
stable liver-like in vitro model for continuous investigations of the hepatic kinetics of 
drugs and DDIs, which well predict the situation in vivo in human. 
 
 
4.4 PAPER IV - IN VIVO DRUG METABOLIC PATHWAY IN HEPATIC IN 
VITRO SYSTEMS 
 
To investigate the metabolite profile in HepaRG cells compared to primary human 
hepatocytes and human in vivo data, AZD6610 and diclofenac, showing both phase I 
and phase II metabolism, were used as model substrates. The metabolite profiles were 
evaluated in suspension, on day 0, and in bioreactor culture 6-7 days after cell 
isolation/thawing (Paper IV). 
 
One of the model substances, AZD6610, is mainly metabolized via hydroxylation to 
M6, followed by further oxidation to M5 and M3, while low levels of the glucuronide 
M10 are detected in human in vivo (unpublished results; Figure 11). In Paper IV, all 
major human in vivo relevant AZD6610 metabolites were detected in fresh and 
cryopreserved human hepatocyte suspensions and the hydroxylation pathway was 
found to be the major route of metabolism. In HepaRG cells, a high level of the 
glucuronide M10 was detected, whereas the level of metabolites in the hydroxylation 
pathway was low or absent. Thus, the main difference between primary human 
hepatocytes and HepaRG cells was the balance between the hydroxylation route, which 
was favoured in human hepatocytes, and the glucuronidation route, which was favoured 
in HepaRG cells (Figure 11). Three P450 enzymes, which are normally not involved in 
the metabolism of drugs, were identified to take part in the hydroxylation of AZD6610 
to M6. The lower expression of two of these enzymes, CYP2J2 and CYP4A11, in the 
HepaRG cells compared to primary human hepatocytes, may be the reason for the 
difference in the capacity to produce the major in vivo metabolites in the hydroxylation 
pathway in the two cell systems. Further, the much higher expression of UGT1A6 in 
HepaRG cells as compared to primary human hepatocyte may explain the efficient 
glucuronidation pathway in the HepaRG cells. Moreover, the metabolite profiles of 
AZD6610 in fresh human hepatocytes and in HepaRG cells cultured in the bioreactor 
for 6 days were similar compared to the metabolite profile in suspension on day 0, 
although the relative levels of the metabolites in the bioreactor were lower. 
 
 
 
   41 
 
 
Figure 11. Overview of tentative structures and suggested major metabolic pathways of AZD6610. The 
hydroxylation pathway was major in vivo in human and in primary human hepatocytes, whereas the 
glucuronidation pathway was major in HepaRG cells. Enzymes involved in the hydroxylation and 
glucuronidation of AZD6610 are shown in the figure. The asterisk denotes the position of the 
14
C label. 
From Darnell et al., Figure 4 (Paper IV). 
 
 
Diclofenac is a carboxylic acid metabolized by both P450s and UGTs. The main human 
in vivo metabolites reported are 4-hydroxydiclofenac, diclofenac acyl glucuronide and 
4-hydroxydiclofenac acyl glucuronide (Riess et al., 1978; Stierlin et al., 1979; Stierlin 
and Faigle, 1979). The initial hypothesis was that the clearance of diclofenac in vivo 
in human was dominated by the formation of 4-hydroxydiclofenac catalyzed by 
hepatic CYP2C9 (Stierlin and Faigle, 1979; Transon et al., 1995; Kumar et al., 
2006b; Kumar et al., 2006a). However, more recent studies revealed that the 
diclofenac acyl glucuronide was hydroxylated via CYP2C8 in vitro (Kumar et al., 
2002). Thus, the excreted 4-hydroxydiclofenac acyl glucuronide may be formed via 
two separate pathways in vivo and the glucuronidation pathway might play an 
important role in the clearance of diclofenac (Figure 12B). 
 
In Paper IV, a clear difference was observed when comparing the metabolic pathways 
of diclofenac in HepaRG cells and primary human hepatocytes. The diclofenac acyl 
glucuronide level was high in HepaRG cell suspension but absent in human hepatocyte 
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suspension. Previous studies have shown that CYP2C8 mRNA expression correlated 
well with CYP2C8 activity (Ohtsuki et al., 2012). Therefore, the low mRNA 
expression of CYP2C8 in differentiated HepaRG cells (Kanebratt and Andersson, 
2008b; Antherieu et al., 2010) may results in a low capacity to hydroxylate the 
diclofenac acyl glucuronide. In contrast, the higher expression of CYP2C8 in human 
hepatocytes may result in depletion of diclofenac acyl glucuronide, the intermediate 
metabolite, in human hepatocytes. Although notable higher level of hydroxydiclofenac 
was observed in human hepatocytes compared to HepaRG cells in Paper IV, the 
hydroxydiclofenac acyl glucuronide was detected at similar levels in HepaRG cells and 
human hepatocytes, which may be explained by the two different pathways, which both 
end up in hydroxydiclofenac acyl glucuronide. 
 
In the bioreactor experiments, 6 days after cell inoculation, hydroxylated and 
glucuronidated metabolites were detected in both fresh human hepatocyte and HepaRG 
bioreactors but the clearance of diclofenac and formation rates of metabolites were 
lower compared to suspension experiments (Figure 12A). In addition, diclofenac acyl 
glucuronide, which was not detected in human hepatocyte suspension, was detected in 
human hepatocyte bioreactor. The high level of diclofenac metabolites detected in 7 
days old “fresh” human hepatocytes cultured in bioreactors in Paper IV is in sharp 
contrast to the decrease of hydroxydiclofenac in human hepatocytes, by approximately 
90%, after 3 days culture in 2D, when compared to fresh hepatocytes (Rodríguez-
Antona et al., 2002). Furthermore, glucuronides are generally too polar to pass 
membranes via passive diffusion (Zamek-Gliszczynski et al., 2006; Lagas et al., 2010), 
thus, the detection of glucuronides in the bioreactor medium indicated an active efflux 
of conjugated metabolites from 7 days old human hepatocytes cultured in the bioreactor 
back to the circulating medium. 
 
Metabolism in the liver is one of the important determinants of the overall disposition 
of drugs and metabolites formed can have an impact on efficacy and safety in humans. 
Comparisons of in vitro metabolite profiles across species can provide an early signal if 
new drug candidates could have different major metabolic pathways in human than in 
the animal species used for safety evaluations. Thus, liver in vitro systems that reliably 
can predict human in vivo metabolic pathways are highly desired. 
 
Freshly isolated human hepatocytes are known to rapidly lose liver phenotypic 
functions including drug metabolism capacity in vitro (Rodríguez-Antona et al., 2002). 
The liver bioreactor using both fresh human hepatocytes and HepaRG cells retained 
biotransformation capacity for at least one week, which is a compelling feature of the 
3D model enabling detection of metabolites from slowly metabolized drugs.  
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Figure 12. (A) The retained P450 and UGT activities in “fresh” human hepatocytes on culture day 6 in 
bioreactors compared to fresh human hepatocytes in suspensions on day 0. The results are given as 
percent of total detected radioactivity and the data points are mean values ± SD, n=3. (B) Major 
metabolic pathways of diclofenac in HepaRG cell and human hepatocyte suspensions and in vivo in 
human. The main P450 and UGT enzymes (Kumar et al., 2002; Sakaguchi et al. 2004; Kuehl et al., 2005; 
Kumar et al. 2006a) involved in the biotransformation and the relative level of metabolites detected in 
each system are presented in B. From Darnell et al., Figure 6 and 7 (Paper IV). 
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4.5 PAPER V - OATP1B1 AND CYP3A4 ACTIVITIES IN 3D HEPATOCYTE 
BIOREACTORS  
 
In Paper V, the OATP1B1 and CYP3A4 protein expression and activities were 
evaluated in up to 9 days old “fresh” human hepatocytes and cryopreserved 
differentiated HepaRG cells cultured in a bioreactor. The OATP1B1-mediated transport 
was assessed by measuring the time-dependent loss from media of E17βG, an OATP1B1 
substrate, with and without E3S, which is an OATP1B1 inhibitor. A significant loss of 
E17βG from the bioreactor media was observed in fresh human hepatocytes on culture 
day 2 (p < 0.05) (Figure 14). On day 7, two out of three donors showed an OATP1B1-
mediated loss from media of E17βG (p > 0.05). In HepaRG cells, a significant 
OATP1B1-mediated loss from media was observed on culture day 2 (p < 0.05), but the 
results showed no OATP1B1 activity on day 7 (p > 0.05) (Figure 14).  
 
 
 
Figure 13. Immunohistochemical staining (brown) of the basolateral uptake transporter OATP1B1 and 
the metabolic enzyme CYP3A4 in bioreactor tissue of fresh human hepatocytes from donor 3 (A and C) 
and HepaRG cells (B and D) cultured for 9 days. OATP1B1 is evenly distributed throughout the whole 
cell membrane in the bioreactor tissue. Magnification: 40-fold. From Ulvestad et al., Figure 8 (Paper V). 
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Figure 14. Time-dependent loss from media of 
3
H-E17βG in fresh human hepatocytes (A and B) and 
HepaRG cells (C and D) without (■; solid lines) and with (□; dotted lines) co-incubation of E3S at day 2 
and day 7 in bioreactor culture. The medium concentration is expressed as % of start concentration 
E17βG. Each point represents the mean +/- S.D., n = 2-3. Where the vertical error bars are not shown, the 
S.D. values are within the limits of the symbols. From Ulvestad et al., Figure 4 (Paper V). 
 
The activity data were in agreement with immunohistochemical staining, which 
showed that OATP1B1 protein expression was preserved for at least 9 days in fresh 
human hepatocytes cultured in 3D (Figure 13A), while OATP1B1 protein expression 
was almost absent in HepaRG cells on culture day 9 (Figure 13B). The maintained 
OATP1B1 activity and protein expression in fresh human hepatocytes is in sharp 
contrast to the extensive decrease in OATP1B1/1B3 activity and protein expression in 
plated (2D) fresh human hepatocytes, when cultured for more than 2 hours (Ulvestad et 
al, 2011).  
 
Further, a significant OATP1B1-mediated uptake of E17βG was observed in HepaRG 
cells, fresh and cryopreserved human hepatocytes in suspension on day 0 (Figure 15A-
C). However, the OATP1B1-mediated transport was significantly higher in fresh and 
cryopreserved human hepatocytes than in HepaRG cells. The OATP1B1 activity data 
are consistent with the mRNA expression of OATP1B1 in cell suspensions showing a 
significantly lower gene expression in HepaRG cells than in both fresh and 
cryopreserved human hepatocytes. These data are in agreement with studies comparing 
transporter activity in fresh and cryopreserved human hepatocytes (Badolo et al., 2011), 
and shows the improved functions and properties of cryopreserved cells (Li, 2008). 
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Figure 15. The graphs show a much higher OATP1B1-mediated 
uptake in suspension of fresh human hepatocytes (A), and 
cryopreserved human hepatocytes (B) compared to HepaRG cells 
(C). Each point represents the mean ± S.D., n = 3. From Ulvestad et 
al., Figure 3, (Paper V). 
 
Atorvastatin is a substrate of OATP1B1 and CYP3A4 and has previously been shown 
to induce CYP3A4 expression (Kocarek et al., 2002; Monostory et al., 2009). In Paper 
V, inhibition of atorvastatin uptake by E3S in both fresh and cryopreserved human 
hepatocyte suspension resulted in a significant decreased loss of atorvastatin and 
decreased formation of atorvastatin metabolites.  
 
In the bioreactor, atorvastatin actually increased CYP3A4 expression over time, which 
resulted in an autoinduction in metabolism and increased metabolite formation in the 
consecutive atorvastatin plus E3S experiment (Paper V). Induction of CYP3A4 in 
HepaRG cells in bioreactor culture have previously been demonstrated as discussed in 
Paper III. In Paper V, an induction response by atorvastatin was observed in both 
primary human hepatocytes and HepaRG cells cultured in the bioreactor for 4 days 
after hepatocyte isolation or HepaRG thawing. Further, the CYP3A4 mRNA expression 
and activity in suspension on day 0, the CYP3A4 activity on culture day 3 and the 
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CYP3A4 protein expression (Figure 13C, D) on culture day 9 in the bioreactor were at 
similar levels in fresh human hepatocytes and HepaRG cells (Paper V). 
 
The study in Paper V indicates that fresh human hepatocytes cultured in a 3D 
bioreactor system retain both OATP1B1 transporter and CYP3A4 metabolizing 
activities and protein expression longer than in currently available in vitro models. The 
rapid loss of transporter and enzyme activities in 2D cultures of human hepatocytes are 
a major concern when studying drug uptake, metabolism and extrusion from cells in 
vitro, and prevents reliable long-term studies to be performed (Richert et al., 2006; 
Rodriguez-Antona et al., 2002; Ulvestad et al., 2011). For OATP1B1 substrates, uptake 
transport activities may have important implications for cellular drug concentrations, 
which also effect drug metabolism and possible toxic effects. The 3D bioreactor system 
allows long-term preclinical studies on drug uptake and metabolism, which are 
especially important for slowly metabolized drugs. 
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5 GENERAL DISCUSSION - FUTURE PERSPECTIVES 
 
 
Scientists within the field of pharmaceutical research are continuously exploring and 
validating new in vitro methods to establish reliable assays, which predict the fate of 
the drug in the human body. High throughput methods are required at an early stage, 
whereas the reduced numbers of drug candidates, in the later drug development phase, 
allow the use of more complex models. The main aim of this thesis was to characterize 
the following in vitro models of the human liver: 
 
 Caco-2 cells 
 HepaRG cells 
 3D culture of fresh human hepatocytes and HepaRG cells 
 
 
5.1 CACO-2 CELLS 
 
Caco-2 cells are polarized cells expressing drug efflux transporters such as P-gp, BCRP 
and MRP2, which are also found in the canalicular membrane of hepatocytes. The 
Caco-2 cells can be used as a model to study hepatic transporter-mediated DDIs of new 
drug candidates. The inhibitor used to block a certain efflux transporter may inhibit 
several other transporters expressed in the Caco-2 cells (Watanabe et al., 2005; Wang 
et al., 2008). The siRNA gene silencing technique, used to knockdown P-gp and MRP2 
in Caco-2 cells in Paper I, was shown to have a great potential in transport-mediated 
DDIs studies to elucidate the function of specific transporters in drug disposition.  
 
 
5.2 HEPARG CELLS 
 
Primary human hepatocytes are the gold standard for hepatic drug metabolism and 
disposition investigations. Due to the restrictions and difficulties involved in the use of 
fresh human hepatocytes, attempts to replace these cells are continuously ongoing. 
Pooled cryopreserved primary human hepatocytes are of good quality, convenient to 
use and provide an average activity of important hepatic enzymes from several donors 
in the same experiment. Anyhow, hepatic immortalized cell lines, human embryonic 
and induced pluripotent stem cell derived hepatocytes would be the ultimate cell system 
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for pharmaceutical research, provided that these cells exhibit all important functions 
found in fresh human hepatocytes. A highly reproducible platform and continuous 
supply of material with maintained hepatic functions over long period of time are 
highly needed. Unfortunately, hepatoma cell lines such as HepG2, C3A and Huh7 cells 
and stem cell derived hepatocytes do not yet fully attain important hepatic functions 
and their utilities and applications within drug development research are limited. 
However, the highly differentiated human hepatoma cell line, HepaRG, has attracted 
great attention after its introduction 2002 (Gripon et al., 2002). The HepaRG cells have 
been extensively evaluated the last decade and the cells exhibit several important 
hepatic functions. The HepaRG cells provide reliable prediction of P450 drug induction 
and drug clearance in vivo in human (Kanebratt and Andersson, 2008a; Zanelli et al., 
2012) and maintain P450 activities in both 2D and 3D culture for several weeks (Jossé 
et al., 2008; Antherieu et al., 2010; Darnell et al., 2011 (Paper III)).  
 
However, the UGT phase II enzyme activity and detailed studies of metabolite profiles 
of drugs in HepaRG cells needed further investigations (Aninat et al., 2006; Jossé et al., 
2008; Antherieu et al., 2010).  In Paper IV, we showed that cryopreserved 
differentiated HepaRG cells exhibit UGT activity both in suspension on day 0 and in 
3D culture for at least one week. The proportion between relevant hydroxylation and 
glucuronidation biotransformation pathways of the two model substrates in Paper IV 
was clearly different in HepaRG cells compared to hepatocytes. The glucuronidation 
pathways were favoured in HepaRG cells, whereas the hydroxylation pathways were 
favoured in primary human hepatocytes. These findings reflects the different mRNA 
expression levels, in HepaRG cells and primary human hepatocytes, of the P450 and 
UGT enzymes involved in the metabolism of the model substrates used in Paper IV. 
 
Although the P-gp and MRP2 efflux activities are high in HepaRG cells, one of the 
most important hepatic uptake function of drugs, the OATP-mediated uptake, was low 
in 2D cultured HepaRG cells (Le Vee et al., 2006).  In Paper V, we showed that the 
OATP1B1 activity in cryopreserved differentiated HepaRG cells in suspension on day 
0 and in 3D culture on day 2 was present, but low compared to primary human 
hepatocytes. The low OATP-mediated uptake in HepaRG cells may affect drug 
clearance, induction, metabolism and toxicity predictions, if the drug is dependent or 
partly dependent of active uptake to enter the cell. Thus, an improved OATP-mediated 
uptake in HepaRG cells would probably increase the applications and improve the in 
vivo predictions in preclinical studies. 
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5.3 3D CULTURE OF FRESH HUMAN HEPATOCYTES AND HEPARG 
CELLS 
 
The high throughput capacity of the conventional 2D cell culture systems and 
suspension experiments is of high importance early in the preclinical phase of drug 
development, when selecting drugs with the right properties for further evaluations. 
However, the selection of metabolic stable drugs requires in vitro systems with 
preserved uptake processes and increased incubation times, which facilitate the 
prediction of clearance and metabolite profiles of slowly metabolized drugs. In 
addition, maintained hepatic functions and co-culture with all relevant cells in the liver 
tissue open up for long term toxicological investigations.  
 
The multicompartment bioreactor evaluated in Paper II, III, IV and V retained hepatic 
functions important for drug metabolism and disposition in the human liver. The P450 
and UGT activities were preserved in fresh human hepatocytes and HepaRG 
bioreactors for at least one week. In addition, the OATP1B1 protein expression and 
uptake activity were detected in fresh human hepatocytes after one week culture in the 
bioreactor. This is to be compared with the rapid loss of P450 and OATP1B1/1B3 
activities reported previously in 2D cultured hepatocytes (Rodríguez-Antona et al., 
2002; Ulvestad et al., 2011). However, although metabolism and transporter functions 
were maintained, the activities decreased with time. Thus, further development and 
improvement of the bioreactor culture may result in even higher enzyme activity and 
prolonged incubation times. The development may include further medium 
optimization, coating of capillaries and co-culture with other cell types. Furthermore, 
the quality of the fresh human hepatocyte preparations is important for the preservation 
of hepatic functions in the bioreactor. In Paper VI and V, the initial release of AST and 
ALT was much higher in donor 2 compared to donor 1 and 3, which resulted in lower 
metabolism and uptake activity in the bioreactor culture. Immortalized cell lines, such 
as HepaRG cells, provide a more reliable and stable quality, but do not exhibit as high 
P450 and OATP1B1 activities in the bioreactor as the human hepatocytes. 
 
Moreover, in Paper III a different protocol for the culture and differentiation of 
HepaRG cells in the bioreactor was applied as compared to Paper IV and V. In Paper 
III, the cells were proliferated and differentiated in the bioreactor, whereas 
cryopreserved differentiated HepaRG cells were directly inoculated at high density in 
the bioreactors used in Paper IV and V, to shorten the experimental period. Only 
hepatocyte-like cells seems to be selected in the cryopreservation of HepaRG cells and 
previous studies have revealed that no or few biliary-like cells are detected when 
hepatocyte-like cells are seeded at high density (Aninat et al., 2006; Cerec et al., 2007). 
Thus, the co-culture of hepatocyte-like and biliary-like cells seen in the bioreactor in 
Paper III, when undifferentiated cells were proliferated and differentiated in the 
bioreactor, may not have been present in Paper IV and V, where cryopreserved 
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HepaRG cells were inoculated at high density. The co-culture of the two cell types in 
3D may be important for the functionality of the HepaRG cells, which should be further 
investigated.  
 
In addition to the evaluation of the retained hepatic function in the bioreactors, the 
prediction of DDIs was investigated. 3D cultured HepaRG cells predicted well the 
P450 inhibition and induction observed in vivo. Further, OATP1B1 inhibition and 
CYP3A4 autoinduction were observed in both fresh human hepatocytes and in 
HepaRG cells cultured in the bioreactor in Paper V.  
 
However, there are other promising 3D culture systems, besides the hollow fiber 
bioreactor investigated in this thesis, which retain important hepatic functions for drug 
metabolism and toxicity investigations (Domansky et al., 2010; Wang et al., 2010; 
Leite et al., 2011; Tostões et al., 2011). 
 
Tostões et al. (2011) showed that alginate encapsulated primary rat hepatocyte 
spheroids cultured in controlled stirred bioreactors with perfusion and constant pH, 
temperature, and oxygen levels maintained urea, albumin synthesis and P450 activity 
for 3 weeks. The same culture system was used to culture primary human hepatocytes, 
which maintained gene expression of phase I and phase II drug metabolizing enzymes 
as well as albumin and urea synthesis for two weeks, although the urea synthesis was 
decreased with time (Tostões et al., 2012). Further, immunostaining showed that 
CYP3A enzymes and bile canaliculi function were retained in human hepatocyte 
spheroids after 2 weeks culture (Tostões et al., 2012). Leite et al. (2011) showed that 
co-cultures of freshly isolated rat hepatocytes with mouse embryonic fibroblast in 
spheroids in bioreactors improved the albumin secretion rate and the phase I and phase 
II enzymatic activities compared to monocultures of hepatocytes in an identical 
bioreactor.  
 
Furthermore, Domansky and co-workers (2010) described a perfused liver cell culture 
in a multiwell plate format suitable for higher throughput applications. Immunostaining 
of the formed 3D microtissue units showed albumin in rat hepatocytes on day 7 and the 
presence of Kupffer cells and stellate cells on day 13. Further, the retention of the liver 
sinusoidal endothelial cell phenotype up to day 13 was dependent on the flow rate and 
the oxygen concentration in the perfused multiwell system. 
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In addition to the 3D systems reported in the literature, there are a number of 
companies that have developed liver 3D systems, which are commercially available. 
Cellasic
(1)
, a company in California, present a high throughput microfluidic perfusion 
array capable of maintaining liver-specific activity in cultured primary hepatocytes for 
over 12 days after plating. Microfabricated “endothelial-like” barriers are separating the 
cords of cultured hepatocyte from the continuous medium flow in micro-capillary 
channels and the P450 activity and inducibility were maintained over time. (Lee et al., 
2010, Poster
(2)
).  
 
Moreover, InSphero
(3)
, a company in Switzerland, offer a static 3D rat liver microtissue 
(rLiMT) system with hanging drop formations, which retains albumin secretion and 
CYP3A4 induction up to three weeks. Moreover, immunofluorescence imaging of the 
hanging drop showed bile canalicular networks. In addition, co-culture of primary rat 
hepatocytes with Kupffer cell enabled the detection of a toxicological effect in 
lipopolysaccharides (LPS)-treated cultures. Another static 3D system, that offers 
functional human liver tissue over a long period of time, is provided by Regenemed
(4)
. 
Co-cultures of liver cells are grown in a transwell system and long term toxicity can be 
assessed. 
 
Some of the 3D in vitro liver systems available today for culture of primary hepatocyte 
provide a controlled environment, oxygen supply, a perfused 3D culture, cell-cell 
contact and co-culture with other cell types. Parameters that seem to be important for 
the retention of urea and albumin synthesis, phase I and phase II activities, in vivo-like 
tissue formation and detection of drug toxicity. However, the localization and function 
of important drug transporters need further investigations and validation of the 3D 
systems to predict DDIs and toxicity is still required. 
 
The 3D bioreactor used in this thesis, together with other available 3D culture systems, 
open up for long-term cultures required for detection of metabolites from slowly 
metabolized drugs as well as induction, DDI and toxicity investigations. Hopefully, the 
use of liver 3D culture system within the pharmaceutical research will contribute to a 
more effective drug development program, which results in safer drugs for the patients.  
 
 
 
 
 
 
(1) www.cellasic.com  
(2) Lee P, Allen M, and  Hung P. (2010) Microfluidic Hepatocyte Array for Long Term Drug. Exposure Screening. 
(3) www.insphero.com 
(4) www.regenemed.com 
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6 CONCLUSIONS 
 
 
In this thesis, the presence and stability of important hepatic functions of the human 
liver were evaluated in HepaRG cells and in primary human hepatocytes using both 
suspension and a dynamic three-dimensional bioreactor system. In addition, in vivo 
relevant drug-drug interaction predictions in the bioreactor and in P-gp and MRP2 
Caco-2 knockdown cells were investigated. The following conclusions can be drawn 
from the results: 
 
 P450, UGT and OATP1B1 activities were maintained for at least one week in 
fresh human hepatocyte cultured in bioreactors. 
 
 CYP1A1/2, CYP2B6, CYP2C9 and CYP3A4 activities were retained in 
HepaRG bioreactors over several weeks allowing the performance of long term, 
sequential studies using the same system. 
 
 Effects of rifampicin and ketoconazole on P450 activities in HepaRG bioreactor 
predicted well the effects observed in vivo. 
 
 UGT activity was present in cryopreserved differentiated HepaRG cell 
suspension and retained for at least one week in HepaRG bioreactor. 
 
 The proportion between relevant hydroxylation and glucuronidation 
biotransformation pathways of the two model substrates in Paper IV was clearly 
different in HepaRG cells compared to hepatocytes. The glucuronidation 
pathways were favoured in HepaRG cells, whereas the hydroxylation pathways 
were favoured in primary human hepatocytes. 
 
 OATP1B1 protein expression and activity were lower in HepaRG cells 
compared to primary human hepatocytes. 
 
 Immunohistochemical characterization of fresh human liver cells and HepaRG 
cells cultivated in bioreactors over two weeks showed formation of tissue-like 
structures and a co-culture of hepatocytes and biliary cells. The hepatocytes 
were polarized and resembled the histology of human liver tissue. 
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 Knockdown of drug transporters using shRNA is a valuable tool to predict 
potential sites of transporter-mediated pharmacokinetic interactions and the 
involvement of hepatic transporters in drug disposition. 
 
 The 3D model is a compelling feature, which open up for long-term cultures 
required for detection of metabolites from slowly metabolized drugs as well as 
induction, DDI and toxicity investigations. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
 
Syftet med läkemedel är att förbättra hälsa och öka överlevnad hos patienter världen 
över. Läkemedel kan dock ge biverkningar, toxiska effekter samt för låg terapeutisk 
effekt, särskilt när patienter tar många läkemedel samtidigt. Kroppen har en 
skyddsmekanism för att avlägsna främmande och potentiellt giftiga ämnen, där levern, 
kroppens reningsverk, utgör en viktig roll. Det är samspelet mellan 
läkemedelstransportörer och metaboliserande enzymer i levern, tarmen, njurarna och i 
andra vävnader som möjliggör att läkemedel tas upp, omvandlas eller bryts ner 
(metaboliseras) till mer lättlösliga produkter som lättare utsöndras i galla och urin. 
Många läkemedel transporteras av samma transportörer och metaboliseras av samma 
enzymer, vilket kan orsaka läkemedelsinteraktioner när en patient får två eller fler 
läkemedel samtidigt. Interaktioner inträffar exempelvis när kroppen bryter ned två 
läkemedel på samma sätt med hjälp av samma leverenzym eller när flera läkemedel 
utsöndras via samma transportör, vilket kan medföra att koncentrationener av läkemedlet 
blir för höga i blod och vävnader. För höga läkemedelskoncentrationer kan leda till 
biverkningar och toxicitet. För att förutsäga och studera samspelet mellan dessa 
komplicerade processer behövs ett testsystem som bevarar leverns funktioner. Eftersom 
läkemedelsmetabolism skiljer sig åt mellan djur och människor är det viktigt att 
använda humana celler.  Problemet är att leverceller förlorar sin förmåga att 
metabolisera och transportera läkemedel inom några få timmar eller få dagar efter det 
att levercellerna har överförts från sin naturliga miljö i levern till en odlingsplatta. 
Läkemedelstester i leverceller som har minskad eller förlorad funktion kan leda till 
felaktiga slutsatser som kan medföra risker för patienter som tar läkemedlet samt orsaka 
att läkemedelsprojekt stoppas sent i utvecklingen eller dras tillbaka från marknaden. 
En idé för att bevara levercellernas funktioner är att odla cellerna i en miljö som 
efterliknar levern så mycket som möjligt. I mitt projekt har vi odlat humana primära 
leverceller och en levercellinje (HepaRG) i en bioreaktor som möjliggör en 
tredimensionell odling. Bioreaktorn är uppbyggd av kapillärer där medium och luft 
cirkulerar för att förse cellerna, som är placerade mellan kapillärerna, med energi och 
syre, samt transportera bort slaggprodukter. Mellan kapillärerna bygger cellerna upp en 
vävnadslik struktur. Cellerna får då den viktiga cell-cell kontakten som behövs för att 
bevara viktiga funktioner och uttrycker läkemedelstransportörer i cellmembranen. Vi 
har sett att levercellerna i bioreaktorn transporterar och metaboliserar läkemedel i minst 
en vecka till skillnad från några timmar till några dagar i odlingsplattor. Det var också 
möjligt att förutse läkemedelsinteraktioner som tidigare upptäckts när patienter tagit 
flera läkemedel samtidigt. Bioreaktorn öppnar upp för långtidsstudier av långsamt 
metaboliserande läkemedel som kräver långa inkubationstider samt studier av 
induktion, läkemedelsinteraktioner och kronisk toxicitet, vilket kan bidra med viktig 
information för att kunna utveckla ett säkert läkemedel som används på rätt sätt. 
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